var title_f2_17_2320="Proximal phalanx transverse fracture AP xray";
var content_f2_17_2320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse fractures of the proximal phalanx: AP x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 337px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior (AP) radiograph shows a transverse fracture of the proximal phalanx (white arrow). Note the the slight angulation of the two major fragments and the diastasis on the side adjacent to the arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2320=[""].join("\n");
var outline_f2_17_2320=null;
var title_f2_17_2321="Cecal bascule - Abdominal films";
var content_f2_17_2321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Cecal bascule - Abdominal films",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain x-ray in a 51-year-old male with generalized abdominal pain showing a distended cecum cranially displaced to the epigastrium. An air fluid level is demonstrated in the cecum in the upright examination (A, arrow) while a moderate amount of stool is seen within the dilated cecum in the supine view (B, arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2321=[""].join("\n");
var outline_f2_17_2321=null;
var title_f2_17_2322="Cotton wool spots";
var content_f2_17_2322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67621%7ERHEUM%2F50474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67621%7ERHEUM%2F50474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cotton wool spots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cotton wool spots are indicative of retinal ischemia. The differential diagnosis includes diabetes, hypertension, AIDS, and the retinal vascular changes of systemic lupus erythematosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal disease in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of the retina from a patient with systemic lupus erythematosus shows multiple peripapillary cotton wool spots, hemorrhage, and a central retinal artery occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2322=[""].join("\n");
var outline_f2_17_2322=null;
var title_f2_17_2323="Patient information: Common finger injuries (The Basics)";
var content_f2_17_2323=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17187\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/3/39998\">",
"         Boutonniere deformity",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/17/1296\">",
"          Jersey finger",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/48/4879\">",
"           Mallet finger",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/10/19631\">",
"            Trigger finger",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33874\">",
"         Patient information: Finger dislocation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/5/3155\">",
"         Patient information: Finger fracture (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/15/10482\">",
"         Patient information: Tenosynovitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25937\">",
"         Patient information: Cast and splint care (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Common finger injuries (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/common-finger-injuries-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27081942\">",
"      <span class=\"h1\">",
"       What are common finger injuries?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common finger injuries include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Finger sprain &ndash; A sprain is when a ligament tears or gets stretched too much. Ligaments are tough bands of tissue that connect bones to other bones. Symptoms of a finger sprain can include finger pain, swelling, stiffness, or weakness.",
"       </li>",
"       <li>",
"        Flexor tendon injury &ndash; Tendons are strong bands of tissue that connect muscles to bones. In a flexor tendon injury, a tendon on the palm side of the hand is torn or cut. If the cut or tear is near the tip of the finger, it keeps the finger tip from being able to bend. The finger tip stays straight. Doctors sometimes use the term &ldquo;jersey finger&rdquo; to describe this injury (",
"        <a class=\"graphic graphic_picture graphicRef61721 \" href=\"UTD.htm?1/17/1296\">",
"         picture 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Extensor tendon injury &ndash; In this injury, a tendon on the back of the hand is torn or cut. If the tear or cut is near the tip of the finger, it causes the tip of the finger to stay bent. The finger is unable to straighten. One common type of extensor tendon injury is called &ldquo;mallet finger&rdquo; (",
"        <a class=\"graphic graphic_picture graphicRef74506 \" href=\"UTD.htm?4/48/4879\">",
"         picture 2",
"        </a>",
"        ). This happens when the finger joint closest to the fingernail gets hurt. Besides making the finger tip bent, mallet finger causes pain and swelling on top of the joint.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Another common type of extensor tendon injury is called a &ldquo;boutonniere deformity.&rdquo; This happens when the tendon tears and slips out of place. It makes the finger joint nearest the tip of the finger stay straight, and the finger joint in the middle of the finger stay bent (",
"      <a class=\"graphic graphic_figure graphicRef69947 \" href=\"UTD.htm?39/3/39998\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Trigger finger &ndash; This condition keeps a person&rsquo;s finger from straightening normally. When people try to straighten their finger, the finger &ldquo;locks&rdquo; or &ldquo;catches&rdquo; in a bent position (",
"        <a class=\"graphic graphic_picture graphicRef80186 \" href=\"UTD.htm?19/10/19631\">",
"         picture 3",
"        </a>",
"        ). Trigger finger can also cause pain in the finger or palm. Trigger finger is caused by a problem with a tendon.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27081957\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your symptoms and do an exam. He or she will probably do an X-ray of your finger or hand. He or she might also do an imaging test such as a CT or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27081972\">",
"      <span class=\"h1\">",
"       How are finger injuries treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of finger injury you have and how severe it is.",
"     </p>",
"     <p>",
"      If you have a lot of pain or a severe injury, your doctor will prescribe a strong pain medicine. If your injury is mild, your doctor might recommend that you take an over-the-counter medicine for your pain. Over-the-counter medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      Treatments for your finger injury can include 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Resting your hand",
"       </li>",
"       <li>",
"        Keeping your hand raised above the level of your heart (when possible)",
"       </li>",
"       <li>",
"        Putting ice on your finger &ndash; To reduce swelling, you can put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. You should put a thin towel between the ice (or other cold object) and your skin. You should use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"       <li>",
"        Wearing an elastic bandage (such as an ACE&trade; wrap)",
"       </li>",
"       <li>",
"        Buddy taping &ndash; Buddy taping involves taping your injured finger to the finger next to it. This is done most often to treat finger sprains. It is not done to treat tendon injuries or trigger finger.",
"       </li>",
"       <li>",
"        Wearing a splint &ndash; Splints are usually used to treat tendon injuries and trigger finger. For some of these injuries, such as mallet finger, people need to wear their splint at all times.",
"       </li>",
"       <li>",
"        Surgery &ndash; Some people need surgery to fix a ligament or tendon. Hand surgery is usually done by a specialist called a hand surgeon.",
"       </li>",
"       <li>",
"        Physical therapy &ndash; After your injury has healed, your doctor might recommend that you work with a physical therapist (exercise expert). He or she can teach you exercises to strengthen your fingers and help them move more easily.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27081987\">",
"      <span class=\"h1\">",
"       How long do finger injuries take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Finger injuries can take weeks to months to heal, depending on the type of injury.",
"     </p>",
"     <p>",
"      It also depends on the person. Healthy children usually heal very quickly. Older adults or adults with other medical problems can take much longer to heal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27082002\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your finger injury is healing. For example, you might not be allowed to bend or straighten your finger for a certain amount of time. Your doctor might also recommend that you avoid certain activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27082017\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will tell you when to call him or her. In general, you should call him or her if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have severe pain, or your pain or swelling gets worse.",
"       </li>",
"       <li>",
"        You have numbness or tingling in your fingers, or your fingers look blue or purple.",
"       </li>",
"       <li>",
"        You bent or straightened your finger, and you weren&rsquo;t supposed to bend or straighten it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27082032\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=see_link\">",
"       Patient information: Finger fracture (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33874?source=see_link\">",
"       Patient information: Finger dislocation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=see_link\">",
"       Patient information: Tenosynovitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       Patient information: Cast and splint care (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/17/2323?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17187 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2323=[""].join("\n");
var outline_f2_17_2323=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27081942\">",
"      What are common finger injuries?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27081957\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27081972\">",
"      How are finger injuries treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27081987\">",
"      How long do finger injuries take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27082002\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27082017\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27082032\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/3/39998\">",
"      Boutonniere deformity",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/17/1296\">",
"       Jersey finger",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/48/4879\">",
"        Mallet finger",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/10/19631\">",
"         Trigger finger",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33874?source=related_link\">",
"      Patient information: Finger dislocation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/5/3155?source=related_link\">",
"      Patient information: Finger fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/15/10482?source=related_link\">",
"      Patient information: Tenosynovitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2324="Female genital tract infections";
var content_f2_17_2324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Female genital tract infections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2324=[""].join("\n");
var outline_f2_17_2324=null;
var title_f2_17_2325="Dalteparin: Patient drug information";
var content_f2_17_2325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dalteparin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     see \"Dalteparin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fragmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fragmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dalteparin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to pork products, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you know that you will not take the drug as you have been told.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin on the right or left side of the stomach, thigh, or buttocks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12352 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2325=[""].join("\n");
var outline_f2_17_2325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156480\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156481\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028825\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028827\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028826\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028831\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028832\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028834\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028829\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028830\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028835\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028836\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=related_link\">",
"      Dalteparin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2326="Olmesartan: Pediatric drug information";
var content_f2_17_2326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Olmesartan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8583?source=see_link\">",
"    see \"Olmesartan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10677?source=see_link\">",
"    see \"Olmesartan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benicar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Olmetec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1028372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin II Receptor Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1028404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8583?source=see_link\">",
"      see \"Olmesartan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider lower starting dose in patients with possible depletion of intravascular volume (eg, patients receiving diuretics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 years and &ge;5 kg: Limited data available: Initial: 0.3 mg/kg/dose once daily; if initial response inadequate after 2 weeks, dose may be increased to 0.6 mg/kg/dose once daily. Dosing was evaluated in a double-blind, placebo-controlled study of 59 patients and some efficacy was demonstrated; however, results were not statistically significant (NCT00151775, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 6-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 to &lt;35 kg: 10 mg once daily; if initial response inadequate after 2 weeks, dose may be   increased (maximum: 20 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;35 kg: 20 mg once daily; if initial response inadequate after 2 weeks, dose may be increased (maximum: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &gt;16 years: Initial: 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks. May administer with other antihypertensive agents if blood pressure inadequately controlled with olmesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks. May administer with other antihypertensive agents if blood pressure inadequately controlled with olmesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No specific guidelines for dosage adjustment; patients undergoing hemodialysis have not been studied.",
"     <b>",
"      Note:",
"     </b>",
"     In patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute), the AUC was tripled after repeated dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No initial dosage adjustment necessary.",
"     <b>",
"      Note:",
"     </b>",
"     In patients with moderate hepatic impairment, an increase in AUC of ~60% was observed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as medoxomil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benicar&reg;: 5 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1028410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1028392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1028373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with other antihypertensive agents (FDA approved in ages 6-16 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benicar&reg; may be confused with Mevacor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, CPK increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, pharyngitis, rhinitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, alopecia, anaphylaxis, angioedema, arthritis, gastroenteritis, hypercholesterolemia, hyperkalemia, hyperlipidemia, hyperuricemia, liver enzymes increased, peripheral edema, rhabdomyolysis, serum creatinine increased, sprue-like symptoms, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1028378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to olmesartan, any component, or other angiotensin II receptor blockers",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10484566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function; use is associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure); deterioration may result in oliguria, acute renal failure, or progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation in patients with progressive and/or significant deterioration in renal function. Hyperkalemia may occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution in these patients and with these agents; monitor potassium closely.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1028379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Use with caution in volume-depleted patients (eg, those on thiazide diuretics); correct depletion first or use a lower starting dose. Symptomatic hypotension may occur, especially in patients with an activated renin-angiotensin system (eg, volume- or salt-depleted patients receiving high doses of diuretic agents); use with caution in these patients; correct depletion before starting therapy or initiate therapy at a lower dose. Concomitant use of an ACE inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11279764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect AUC of olmesartan. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F203472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1028412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, serum creatinine, serum potassium",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1028394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Olmesartan produces direct antagonism of the effects of angiotensin II. Unlike the ACE inhibitors, olmesartan blocks the binding of angiotensin II to the AT1 receptor subtype. It produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors. Olmesartan does not affect the ACE (kininase II) or the response to bradykinin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1028396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~17 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Olmesartan medoxomil is hydrolyzed during absorption from the GI tract to active olmesartan. Virtually no further metabolism occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~26%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: All as unchanged drug: Feces (50% to 65%); urine (35% to 50%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 1.3 L/hour; similar data reported in pediatric patients (1-16 years) when adjusted by body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dialysis: Effects of hemodialysis have not been studied",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1028415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10677?source=see_link\">",
"      see \"Olmesartan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication (prescription or OTC) or herbal products during therapy unless approved by prescriber. Do not use potassium supplement or salt substitutes without consulting prescriber. Take exactly as directed. Do not alter dose or discontinue without consulting prescriber. May be taken with or without food. This drug does not eliminate the need for diet or exercise regimen as recommended by prescriber. If you have diabetes, check glucose levels closely (drug may alter glucose levels). May cause headache or dizziness (use caution when driving or engaging in tasks that require alertness until response to drug is known); diarrhea; or back or joint pain (consult prescriber for approved analgesic). Report chest pain or palpitations; unrelieved headache; flu-like symptoms or upper respiratory infection; or other persistent adverse reactions. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F11279784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The antihypertensive effects of olmesartan are smaller in black patients (usually a low-renin patient population); this effect of race is also seen with ACE inhibitors, beta-blockers, and other angiotensin receptor blockers. A pediatric study of olmesartan in patients 6-16 years of age found numerically smaller reductions in blood pressure in black patients compared to a racially-mixed cohort (Hazan, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F9944094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with olmesartan tablets. Combine 50 mL purified water and twenty 20 mg tablets in an 8-ounce amber bottle and allow to stand for &ge;5 minutes. Shake well for &ge;1 minute, then allow to stand for &ge;1 minute. Repeat shaking and standing process four additional times. Add 100 mL Ora-Sweet&reg; and 50 mL Ora-Plus&reg; to the suspension and shake well for &ge;1 minute. Label \"shake well\" and \"refrigerate\".  Stable for 28 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Benicar&reg; prescribing information, Daiichi Sankyo, Inc, Parsippany, NJ, 2010.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hazan L, Hern&aacute;ndez Rodriguez OA, Bhorat AE, et al, \"A Double-Blind, Dose-Response Study of the Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescents With Hypertension,\"",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2010, 55(6):1323-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/17/2326/abstract-text/20385971/pubmed\" id=\"20385971\" target=\"_blank\">",
"        20385971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NCT00151775, \"Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure,\" Unpublished data. Available at:",
"      <a href=\"file://clinicaltrials.gov/ct2/show/NCT00151775?term=olmesartan+children&amp;amp;rank=1\" target=\"_blank\">",
"       file://clinicaltrials.gov/ct2/show/NCT00151775?term=olmesartan+children&amp;rank=1",
"      </a>",
"      .  Date accessed: October 13, 2010.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16034 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2326=[""].join("\n");
var outline_f2_17_2326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709179\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203488\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028372\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028404\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203464\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203451\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028410\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028392\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028373\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914230\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203512\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028378\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484566\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028379\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837691\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203458\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11279764\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203460\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203472\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028412\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028394\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028396\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1028415\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11279784\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9944094\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8583?source=related_link\">",
"      Olmesartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/27/10677?source=related_link\">",
"      Olmesartan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2327="Adenomatoid malform CXR I";
var content_f2_17_2327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61385%7EPULM%2F73128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61385%7EPULM%2F73128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation (Type I) in a newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The initial chest radiograph shows complete opacification of left hemithorax with compression of the right lung, which is hypoplastic and surrounded by a small right pleural effusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation (Type I) in a newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After insertion of a left chest tube, liquid is drained out of a large left lung cyst, which doesn't collapse but fills with air.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2327=[""].join("\n");
var outline_f2_17_2327=null;
var title_f2_17_2328="Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis";
var content_f2_17_2328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Courtney Schadt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2328/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/17/2328/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24503907\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis that presents as an inflammatory and ulcerative disorder of the skin. In contrast to its name, PG is neither an infectious nor gangrenous condition. The most common presentation of PG is an inflammatory papule or pustule that progresses to a painful ulcer with a violaceous undermined border and a purulent base (",
"    <a class=\"graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528 \" href=\"UTD.htm?41/27/42426\">",
"     picture 1A-E",
"    </a>",
"    ). PG may also present with bullous, vegetative, peristomal, and extracutaneous lesions.",
"   </p>",
"   <p>",
"    More than half of patients with PG develop the disorder in association with an underlying systemic disease. Inflammatory bowel disease, hematologic disorders, and arthritis represent the most frequent comorbidities.",
"   </p>",
"   <p>",
"    A diagnosis of PG rests upon the recognition of consistent clinical and histologic findings and the exclusion of other inflammatory or ulcerative cutaneous disorders. There are no pathognomonic clinical or histological findings of PG.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of PG will be discussed here. The treatment and prognosis of PG and other neutrophilic dermatoses are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=see_link\">",
"     \"Pyoderma gangrenosum: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24503914\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PG is a rare disorder with an estimated incidence of 3 to 10 cases per million people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"     1",
"    </a>",
"    ]. Individuals of any age may be affected, including children. PG most commonly develops in young and middle aged adults, with an average age of onset between 40 and 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Between the sexes, women are more frequently affected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24503921\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with its categorization as a neutrophilic dermatosis, PG is characterized by neutrophil-predominant infiltrates in the skin. However, the reason for the development of the inflammatory process that leads to PG remains unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Past theories on the pathogenesis of PG included contributory roles for occult bacterial infection, circulating autoantibodies, and the Shwartzman reaction (a local immune response to bacterial endotoxin resulting in tissue necrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"     6",
"    </a>",
"    ]. As subsequent studies found little support for these theories, abnormalities in neutrophil function, genetic variations, and dysregulation of the innate immune system became the primary factors considered to contribute to the pathogenesis of PG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neutrophil dysfunction",
"      </strong>",
"      &ndash; Neutrophils are prominent in pathology specimens from PG, and the response of PG to anti-neutrophil pharmacologic agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , suggests an important role for these cells. In addition, one study found abnormalities in neutrophil trafficking that may have been related to aberrant intracellular metabolic oscillations in a patient with PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/7\">",
"       7",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic factors",
"      </strong>",
"      &ndash; Genetic susceptibility may contribute to the development of PG. Familial cases of PG have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. In addition, the PAPA syndrome (OMIM #604416), an autosomal dominant disorder characterized by pyogenic sterile arthritis, PG, and acne has been linked to mutations in the",
"      <span class=\"nowrap\">",
"       <em>",
"        PSTPIP1",
"       </em>",
"       /",
"       <em>",
"        CD2BP1",
"       </em>",
"      </span>",
"      gene on chromosome 15q, a gene that encodes",
"      <span class=\"nowrap\">",
"       proline/serine/threonine",
"      </span>",
"      phosphatase-interacting protein 1 (also known as CD2 antigen-binding protein 1) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. Mutations in this gene may promote inflammation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link&amp;anchor=H8#H8\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'PAPA syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Systemic inflammation",
"      </strong>",
"      &ndash; PG often occurs in association with other autoinflammatory disorders (eg, inflammatory bowel disease and arthritis), suggesting that dysregulation of the immune system may contribute to PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"       6",
"      </a>",
"      ]. Increased production of cytokines involved in leukocyte function, such as interleukin (IL)-8 and IL-23, may be relevant factors [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. In addition, the response of PG to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and other anti-tumor necrosis factor (TNF)-alpha agents suggests an important role for TNF-alpha in PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=see_link&amp;anchor=H1797000#H1797000\">",
"       \"Pyoderma gangrenosum: Treatment and prognosis\", section on 'Infliximab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24503928\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of PG are variable, and can be divided into four major subtypes: ulcerative (classic) PG (the most common variant), bullous (atypical) PG, pustular PG, and vegetative PG [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1537182\">",
"    <span class=\"h2\">",
"     Common features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subtypes of PG share a clinical course characterized by the appearance of an inflammatory papule, pustule, vesicle, or nodule that subsequently expands and breaks down to form an erosion or ulcer. With the exception of vegetative PG, lesion development is often rapid and the level of pain is often greater than expected based upon the appearance of the ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/16\">",
"     16",
"    </a>",
"    ]. Fever may or may not be present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pathergy, a term used to describe the induction or exacerbation of PG in sites of incidental or iatrogenic trauma, is frequently mentioned in descriptions of the clinical behavior of PG. However, not all patients with PG exhibit this feature. Data on the proportion of patients with PG who experience pathergy are limited. In a retrospective study of 103 patients with PG, pathergy was documented in the medical records of 31 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373563\">",
"    <span class=\"h2\">",
"     Subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Descriptions of the major variants of PG are provided below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ulcerative (classic) PG",
"      </strong>",
"      &ndash; The ulcerative variant of PG represents the vast majority of cases of PG. Ulcerative PG typically begins as a tender, inflammatory papule, pustule, or vesicle that develops on normal-appearing skin or at a site of trauma (",
"      <a class=\"graphic graphic_picture graphicRef59459 graphicRef53733 \" href=\"UTD.htm?25/38/26217\">",
"       picture 2A-B",
"      </a>",
"      ). The lower extremities and trunk are the most common sites of involvement, though lesions may occur in other areas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The initial inflammatory lesion subsequently expands peripherally and degenerates centrally, leading to ulcer formation (",
"      <a class=\"graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528 \" href=\"UTD.htm?41/27/42426\">",
"       picture 1A-E",
"      </a>",
"      ). The edge of the ulcer usually exhibits a bluish or violaceous color and demonstrates an undermined quality. Irregular expansion of the involved tissue may lead to a serpiginous configuration. The base of the ulcer is purulent and necrotic, and the depth of the ulcer often extends into subcutaneous fat and occasionally reaches the fascia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"       1",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients may have a single lesion or multiple lesions in various stages of development. Ulcers typically resolve with atrophic, cribriform scars.",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous (atypical) PG",
"      </strong>",
"      &ndash; Bullous PG is a less common, superficial variant of PG that is most commonly seen in patients with PG related to hematologic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/3\">",
"       3",
"      </a>",
"      ]. Unlike ulcerative PG, the arms and face are the most common sites of involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. Patients typically present with the rapid development of blue-gray, inflammatory bullae in the involved areas [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/3\">",
"       3",
"      </a>",
"      ]. The bullae quickly erode, resulting in superficial ulcers (",
"      <a class=\"graphic graphic_picture graphicRef55967 \" href=\"UTD.htm?30/56/31618\">",
"       picture 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Due to the strong association between bullous PG and hematologic disease, patients who present without an associated hematologic disorder should be followed closely for the development of a hematologic disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pustular PG",
"      </strong>",
"      &ndash; Pustular PG usually occurs in patients with inflammatory bowel disease, and tends to arise during periods of acute exacerbations of bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/16\">",
"       16",
"      </a>",
"      ]. Affected patients exhibit the rapid development of painful pustules surrounded by erythema (",
"      <a class=\"graphic graphic_picture graphicRef83690 \" href=\"UTD.htm?1/21/1365\">",
"       picture 4",
"      </a>",
"      ). Concomitant fever and arthralgias are common [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"       1",
"      </a>",
"      ]. Pyostomatitis vegetans, which presents with multiple small pustules and erosions on the oral mucosa, may be a variant of pustular PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1,19\">",
"       1,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Vegetative PG",
"      </strong>",
"      &ndash; Vegetative PG (also known as superficial granulomatous pyoderma) is a localized, solitary, superficial form of PG that presents as an indolent, mildly painful nodule, plaque, or ulcer (",
"      <a class=\"graphic graphic_picture graphicRef83904 \" href=\"UTD.htm?18/41/19094\">",
"       picture 5",
"      </a>",
"      ). A verrucous quality is often present. The undermined borders and purulent bases of ulcerative PG are absent. The head and neck are the most common sites for vegetative PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373845\">",
"    <span class=\"h2\">",
"     Special sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the morphologic subtypes reviewed above, other terms have been used to describe certain presentations of PG. Examples include peristomal PG, genital PG, and extracutaneous PG.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Peristomal PG",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Peristomal PG is an uncommon manifestation of PG that is characterized by the development of lesions consistent with ulcerative PG adjacent to a stoma (",
"      <a class=\"graphic graphic_picture graphicRef72285 \" href=\"UTD.htm?36/57/37777\">",
"       picture 6",
"      </a>",
"      ). This typically occurs in patients with ulcerative colitis or Crohn&rsquo;s disease and may develop months to a few decades after placement of a stoma. Trauma caused by maintenance of the stoma or irritation from stoma secretions may play a role in the development of peristomal PG [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Genital PG",
"      </strong>",
"      &ndash; Genital PG may involve the vulva, penis, or scrotum. Lesions resemble those of ulcerative PG (",
"      <a class=\"graphic graphic_picture graphicRef83689 \" href=\"UTD.htm?32/32/33286\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Extracutaneous PG",
"      </strong>",
"      &ndash; Rarely, PG involves extracutaneous sites. In such cases, sterile neutrophilic infiltration develops in sites such as the lungs, intestine, cornea, liver, spleen, heart, bones, muscle, and central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/20-31\">",
"       20-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373281\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 50 percent of patients with PG have an associated systemic disease, most commonly inflammatory bowel disease (14 to 34 percent), arthropathies (11 to 25 percent), and hematologic disease or hematologic malignancy (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. PG may precede or follow the diagnosis of an associated disorder, and may or may not parallel the clinical course of the associated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6,18\">",
"     6,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Inflammatory bowel disease",
"      </strong>",
"      &ndash; PG is one of the most common skin disorders linked to inflammatory bowel disease. The proportion of patients with inflammatory bowel disease who develop PG appears to be small [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In a cohort study of 2402 patients with inflammatory bowel disease, PG was detected in only 0.75 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H5#H5\">",
"       \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Pyoderma gangrenosum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hematologic disorders",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      PG may occur in patients with hematologic disorders or hematologic malignancies. The most common type of paraproteinemia associated with PG is IgA monoclonal gammopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"       6",
"      </a>",
"      ]. Examples of other hematologic disorders that have been associated with PG include myeloma, leukemia, myelodysplasia, lymphoma, and polycythemia vera [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/3,4,6\">",
"       3,4,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Arthritis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      PG may occur in association with rheumatoid arthritis, seronegative arthritis, ankylosing spondylitis, and less frequently, other arthropathies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/3,6\">",
"       3,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       PAPA syndrome",
"      </strong>",
"      &ndash; PAPA syndrome is an autosomal dominant disorder that presents with pyogenic sterile arthritis, PG, and acne. PAPA syndrome occurs secondary to a defect in the",
"      <span class=\"nowrap\">",
"       <em>",
"        PSTPIP1",
"       </em>",
"       /",
"       <em>",
"        CD2BP1",
"       </em>",
"      </span>",
"      gene. (See",
"      <a class=\"local\" href=\"#H24503921\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link&amp;anchor=H8#H8\">",
"       \"Periodic fever syndromes and other autoinflammatory diseases: An overview\", section on 'PAPA syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of additional disorders that have been infrequently linked to PG include hidradenitis suppurativa, pulmonary disease, systemic lupus erythematosus, thyroid disease, solid organ cancers, viral and autoimmune hepatitis, sarcoidosis, and major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Further study is necessary to validate a relationship between these disorders and PG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24503942\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical, histopathologic, and laboratory findings in PG are nonspecific, and a diagnosis of PG can only be made once other diagnostic possibilities have been excluded. At least a clinical history, physical examination, and skin biopsy should be performed in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"     6",
"    </a>",
"    ]. In patients known to have diseases associated with PG, the development of an ulcer should raise suspicion for this diagnosis. In addition, once PG has been diagnosed, patients should be evaluated for the presence of an associated underlying disease. (See",
"    <a class=\"local\" href=\"#H4373281\">",
"     'Associated disorders'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4373929\">",
"     'Laboratory studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H822281\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no universally accepted and validated diagnostic criteria for PG. The diagnostic criteria for ulcerative PG utilized by some authors are provided below [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <strong>",
"     Major criteria (must have both)",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid progression of a painful, necrolytic cutaneous ulcer with an irregular, violaceous, and undermined border (1 to 2 cm per day or 50 percent increase in size within one month)",
"     </li>",
"     <li>",
"      Other causes of cutaneous ulceration have been excluded (usually necessitates skin biopsy and laboratory investigations)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Minor criteria (must have two)",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History suggestive of pathergy or clinical finding of cribriform scarring",
"     </li>",
"     <li>",
"      Systemic disease associated with PG (inflammatory bowel disease, arthritis, IgA gammopathy, or malignancy)",
"     </li>",
"     <li>",
"      Histopathologic findings (sterile dermal neutrophilia, &plusmn; mixed inflammation, &plusmn; lymphocytic vasculitis)",
"     </li>",
"     <li>",
"      Treatment response (rapid response to systemic glucocorticoid treatment)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373914\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical assessment of the patient with a lesion suspicious for PG should include a thorough history and physical examination. Patients should be questioned regarding the history of lesion development, associated symptoms, and personal medical history. Examples of findings attainable via a patient history that support a diagnosis of PG include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid course of lesion development",
"     </li>",
"     <li>",
"      Initial lesion consistent with papule, pustule, or vesicle",
"     </li>",
"     <li>",
"      Pain out of proportion to lesion",
"     </li>",
"     <li>",
"      History of preceding trauma (pathergy)",
"     </li>",
"     <li>",
"      History of disorders associated with PG (see",
"      <a class=\"local\" href=\"#H4373281\">",
"       'Associated disorders'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The physical examination is useful for identifying the extent of disease, narrowing the differential diagnosis, and detecting clinical signs of PG-associated disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373900\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the histopathologic findings of PG are nonspecific, biopsies are most useful for excluding other disorders that may present with similar clinical findings. A biopsy is indicated in patients without a preceding history of PG and in patients with established PG who present with lesions with atypical features or lesions that fail to respond as expected to therapy. Although clinicians are often concerned about biopsy-induced pathergy, the need to rule out other disorders and ensure proper treatment supersedes concern for the induction of an exacerbation of PG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603219\">",
"    <span class=\"h3\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal procedure for biopsy is an elliptical incisional biopsy that incorporates both the inflamed lesion border and ulcer edge and extends vertically into the subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/34\">",
"     34",
"    </a>",
"    ]. A tissue specimen that includes the inflamed border should be sent for routine histopathologic examination and microbial stains. In addition, a specimen from the ulcer should be sent for culture to evaluate for bacterial, fungal, and atypical mycobacterial infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603233\">",
"    <span class=\"h3\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specimens taken from the earliest lesions of PG demonstrate perifollicular inflammation and intradermal abscess formation (",
"    <a class=\"graphic graphic_picture graphicRef55462 graphicRef79287 \" href=\"UTD.htm?17/61/18394\">",
"     picture 8A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/35\">",
"     35",
"    </a>",
"    ]. Once lesions progress to ulceration, epidermal and superficial dermal necrosis with an underlying mixed inflammatory cell infiltrate and abscess formation are typically detected. Giant cells may be found, and tissue from the edge of the lesion may demonstrate vascular changes suggestive of lymphocytic vasculitis. Leukocytoclastic vasculitis may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional findings may be identified based upon the subtype of PG. Specimens from bullous PG demonstrate subepidermal bullae. Pseudoepitheliomatous hyperplasia, sinus tracts, and palisading granulomas are features consistent with vegetative PG.",
"   </p>",
"   <p>",
"    Direct immunofluorescence studies yield nonspecific findings in PG. Deposition of IgM, C3, and fibrin in vessel walls may be detected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"     6",
"    </a>",
"    ]. Because of the nonspecific nature of the results, direct immunofluorescence is usually only conducted when additional clinical findings indicate a need to exclude autoimmune bullous disease, lupus, or vasculitis as a cause of ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714358#H4714358\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4373929\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to tissue biopsies, there are no laboratory studies that provide a definitive diagnosis of PG. Nonspecific findings such as leukocytosis, elevation of the erythrocyte sedimentation rate, and elevation of C-reactive protein levels may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory tests are most useful for narrowing the differential diagnosis and identifying the presence of PG-associated diseases. Recommendations for the work-up of these patients vary. We typically obtain the following studies in patients with clinical and histopathologic findings consistent with PG:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete blood count",
"      </strong>",
"      (to evaluate for underlying hematologic disorders)",
"     </li>",
"     <li>",
"      <strong>",
"       Comprehensive metabolic panel",
"      </strong>",
"      (to evaluate for hepatic or renal dysfunction and glucose abnormalities prior to initiation of systemic glucocorticoids or immunosuppressive agents)",
"     </li>",
"     <li>",
"      <strong>",
"       Antinuclear antibody titer",
"      </strong>",
"      (to evaluate for the presence of systemic lupus erythematosus or collagen vascular disorders in association with PG)",
"     </li>",
"     <li>",
"      <strong>",
"       Antineutrophilic cytoplasmic antibodies",
"      </strong>",
"      (to evaluate for granulomatous vasculitis as a cause of ulceration)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypercoagulability studies",
"      </strong>",
"      (antiphospholipid antibody screen to evaluate for antiphospholipid syndrome as a cause of ulceration; based upon clinical suspicion, other tests to evaluate for thrombotic states [eg, cryoglobulins, Factor V Leiden, methylene tetrahydrofolate reductase]) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Hepatitis panel",
"      </strong>",
"      (to evaluate for associated hepatitis B or C, particularly for patients in whom immunomodulatory therapy is considered)",
"     </li>",
"     <li>",
"      <strong>",
"       Rheumatoid factor",
"      </strong>",
"      (as a component of the evaluation for cryoglobulinemia and rheumatoid arthritis)",
"     </li>",
"     <li>",
"      <strong>",
"       Serum immunofixation electrophoresis",
"      </strong>",
"      (to evaluate for paraproteins)",
"     </li>",
"     <li>",
"      <strong>",
"       Chest radiography",
"      </strong>",
"      (to evaluate for presence of extracutaneous involvement and for possible infection prior to the initiation of immunosuppressive therapy)",
"     </li>",
"     <li>",
"      <strong>",
"       Colonoscopy",
"      </strong>",
"      (to evaluate for underlying inflammatory bowel disease unless another cause of PG is identified)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional tests to evaluate for associated disorders and disorders in the differential diagnosis are ordered based upon clinical suspicion for specific diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4374004\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the lack of a definitive test for PG, misdiagnosis can occur. In one retrospective study, 15 of 157 consecutive patients seen at an academic institution and given a diagnosis of PG (10 percent) were subsequently found to have an alternative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vascular occlusion disorders, venous disease, vasculitis, malignancy, cutaneous infection, drugs, exogenous tissue injury, and ulcerative inflammatory disorders (eg, cutaneous Crohn&rsquo;s disease and ulcerative necrobiosis lipoidica) may be mistaken for PG (",
"    <a class=\"graphic graphic_table graphicRef72103 \" href=\"UTD.htm?40/56/41868\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/36\">",
"     36",
"    </a>",
"    ]. Antiphospholipid-antibody syndrome is one of the most common disorders mistaken for PG; other more commonly confused disorders include venous stasis ulcers, Wegener&rsquo;s granulomatosis, factitial ulcers, sporotrichosis, polyarteritis nodosa, livedoid vasculopathy, angiocentric T cell lymphoma, and cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2328/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical history, biopsy, and directed laboratory studies attained during patient evaluation aid in distinguishing PG from other diseases. Reassessment of a diagnosis of PG is indicated if the disease fails to respond as expected to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=see_link\">",
"     \"Pyoderma gangrenosum: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=see_link\">",
"       \"Patient information: Pyoderma gangrenosum (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H603259\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pyoderma gangrenosum is an uncommon neutrophilic dermatosis that most commonly presents with inflammatory ulcers on the skin. Although PG may occur at any age, there is a predilection for young and middle-aged adults and women. (See",
"      <a class=\"local\" href=\"#H24503914\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The factors that contribute to the development of PG are not well-understood. Factors that are postulated to contribute to PG include aberrant neutrophil function, genetic susceptibility, and dysregulation of the immune system. (See",
"      <a class=\"local\" href=\"#H24503921\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of PG vary. The most common presentation is ulcerative (classic) PG, which typically presents as a rapidly developing, painful purulent ulcer with a violaceous and undermined border (",
"      <a class=\"graphic graphic_picture graphicRef83692 graphicRef72260 graphicRef83691 graphicRef52291 graphicRef52528 \" href=\"UTD.htm?41/27/42426\">",
"       picture 1A-E",
"      </a>",
"      ). Other variants of PG include bullous, pustular, and vegetative presentations. PG may also develop in peristomal, genital, and extracutaneous locations. (See",
"      <a class=\"local\" href=\"#H24503928\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 50 percent of patients with PG have an associated systemic disease. The strongest associations are between PG and inflammatory bowel disease, hematologic disorders, and arthritis. (See",
"      <a class=\"local\" href=\"#H4373281\">",
"       'Associated disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since the clinical and histologic findings of PG are nonspecific, PG is a diagnosis of exclusion (",
"      <a class=\"graphic graphic_table graphicRef72103 \" href=\"UTD.htm?40/56/41868\">",
"       table 1",
"      </a>",
"      ). At a minimum, the patient evaluation should include a patient history, physical examination, and biopsy to detect findings consistent with PG and to rule out other diseases. (See",
"      <a class=\"local\" href=\"#H24503942\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/1\">",
"      Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009; 23:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/2\">",
"      von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/3\">",
"      Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000; 79:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/4\">",
"      Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/5\">",
"      Saracino A, Kelly R, Liew D, Chong A. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol 2011; 52:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/6\">",
"      Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/7\">",
"      Adachi Y, Kindzelskii AL, Cookingham G, et al. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 1998; 111:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/8\">",
"      Alberts JH, Sams HH, Miller JL, King LE Jr. Familial ulcerative pyoderma gangrenosum: a report of 2 kindred. Cutis 2002; 69:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/9\">",
"      Khandpur S, Mehta S, Reddy BS. Pyoderma gangrenosum in two siblings: a familial predisposition. Pediatr Dermatol 2001; 18:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/10\">",
"      al-Rimawi HS, Abuekteish FM, Daoud AS, Oboosi MM. Familial pyoderma gangrenosum presenting in infancy. Eur J Pediatr 1996; 155:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/11\">",
"      Shands JW Jr, Flowers FP, Hill HM, Smith JO. Pyoderma gangrenosum in a kindred. Precipitation by surgery or mild physical trauma. J Am Acad Dermatol 1987; 16:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/12\">",
"      Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/13\">",
"      Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol 2008; 144:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/14\">",
"      Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 2011; 147:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/15\">",
"      Oka M, Berking C, Nesbit M, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000; 80:595.",
"     </a>",
"    </li>",
"    <li>",
"     Powell FC, Hackett BC, Wallach D. Pyoderma gangrenosum. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al.  (Eds), McGraw-Hill Companies, Inc., 2012. Vol 1, p.371.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/17\">",
"      Wong WW, Machado GR, Hill ME. Pyoderma gangrenosum: the great pretender and a challenging diagnosis. J Cutan Med Surg 2011; 15:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/18\">",
"      Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/19\">",
"      Nico MM, Hussein TP, Aoki V, Louren&ccedil;o SV. Pyostomatitis vegetans and its relation to inflammatory bowel disease, pyoderma gangrenosum, pyodermatitis vegetans, and pemphigus. J Oral Pathol Med 2012; 41:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/20\">",
"      Brown TS, Marshall GS, Callen JP. Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: a rarely recognized extracutaneous manifestation of a neutrophilic dermatosis. J Am Acad Dermatol 2000; 43:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/21\">",
"      Fukuhara K, Urano Y, Kimura S, et al. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998; 139:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/22\">",
"      Abdelrazeq AS, Lund JN, Leveson SH. Pouchitis-associated pyoderma gangrenosum following restorative proctocolectomy for ulcerative colitis. Eur J Gastroenterol Hepatol 2004; 16:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/23\">",
"      Nurre LD, Rabalais GP, Callen JP. Neutrophilic dermatosis-associated sterile chronic multifocal osteomyelitis in pediatric patients: case report and review. Pediatr Dermatol 1999; 16:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/24\">",
"      East-Innis A, Desnoes R, Thame K, et al. Pyoderma gangrenosum associated with osteomyelitis in a paediatric patient: a case report. West Indian Med J 2005; 54:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/25\">",
"      Goldshmid O, Dovorish Z, Zehavi T, et al. Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature. Rheumatol Int 2011; 31:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/26\">",
"      Wilson DM, John GR, Callen JP. Peripheral ulcerative keratitis--an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet's syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999; 40:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/27\">",
"      Brown BA, Parker CT, Bower KS. Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum. Cornea 2001; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/28\">",
"      Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea 2007; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/29\">",
"      Vadillo M, Jucgla A, Podzamczer D, et al. Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia. Br J Dermatol 1999; 141:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/30\">",
"      Chanson P, Timsit J, Kujas M, et al. Pituitary granuloma and pyoderma gangrenosum. J Endocrinol Invest 1990; 13:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/31\">",
"      Koester G, Tarnower A, Levisohn D, Burgdorf W. Bullous pyoderma gangrenosum. J Am Acad Dermatol 1993; 29:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/32\">",
"      Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 2008; 87:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/33\">",
"      Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985; 55:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/34\">",
"      Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. The vasculopathic reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.195.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2328/abstract/36\">",
"      Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002; 347:1412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13782 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2328=[""].join("\n");
var outline_f2_17_2328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H603259\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24503907\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24503914\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24503921\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24503928\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1537182\">",
"      Common features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4373563\">",
"      Subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4373845\">",
"      Special sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4373281\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24503942\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H822281\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4373914\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4373900\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H603219\">",
"      - Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H603233\">",
"      - Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4373929\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4374004\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603259\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13782\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13782|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/54/13156\" title=\"picture 1A\">",
"      Pyoderma gangrenosum localized",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/11/17587\" title=\"picture 1B\">",
"      Pyoderma gangrenosum - ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/30/18918\" title=\"picture 1C\">",
"      Pyoderma gangrenosum large ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/57/2964\" title=\"picture 1D\">",
"      Pyoderma gangrenosum - close view of ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/47/7920\" title=\"picture 1E\">",
"      Pyoderma gangrenosum cribriform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/1/6166\" title=\"picture 2A\">",
"      Pyoderma gangrenosum - early lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/17/39187\" title=\"picture 2B\">",
"      Pyoderma gangrenosum early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/56/31618\" title=\"picture 3\">",
"      Pyoderma gangrenosum 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/21/1365\" title=\"picture 4\">",
"      Pustular pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/41/19094\" title=\"picture 5\">",
"      Vegetative pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/57/37777\" title=\"picture 6\">",
"      Pyoderma gangrenosum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/32/33286\" title=\"picture 7\">",
"      Pyoderma gangrenosum on penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/54/20327\" title=\"picture 8A\">",
"      Pyoderma gangrenosum - histopathology dermis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/30/44517\" title=\"picture 8B\">",
"      Pyoderma gangrenosum - histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13782|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/56/41868\" title=\"table 1\">",
"      Pyoderma gangrenosum ddx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/28/29122?source=related_link\">",
"      Patient information: Pyoderma gangrenosum (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=related_link\">",
"      Pyoderma gangrenosum: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2329="Visual impairment in adults: Refractive disorders and presbyopia";
var content_f2_17_2329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Visual impairment in adults: Refractive disorders and presbyopia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Shahzad I Mian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2329/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/17/2329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractive errors are a common, correctable cause of impaired vision throughout the world.",
"   </p>",
"   <p>",
"    The normal eye creates a clear image by bending (refracting) light to focus onto the retina. Refractive errors occur when a component of the eye's optical system fails to focus the optical image.",
"   </p>",
"   <p>",
"    This topic will cover the epidemiology, diagnosis, and treatment of refractive errors in adults. Refractive errors in children and laser refractive treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=see_link\">",
"     \"Laser refractive surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONAL ANATOMY OF THE EYE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye's ability to focus is dependent on the eye's optical system, which consists of two refractive surfaces working in tandem: the cornea and the crystalline lens (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The cornea is the more powerful refractive element, accounting for two thirds of the eye's refractive power. The lens provides the remaining one third, for a total refractive power of 60 diopters (D). Refractive power of the eye and corrective lenses is measured in diopters, where a diopter is the reciprocal of the focal length measured in meters. The focal length is the distance from a lens to its focus or focal point.",
"   </p>",
"   <p>",
"    The cornea has a fixed amount of refractive power while the lens can vary its power by altering its shape [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/1\">",
"     1",
"    </a>",
"    ]. Accommodation is the term used to describe this change in lens shape, which can increase the power of the lens to enable the eye to focus on objects at arm's length or closer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Emmetropia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emmetropia (normal refraction) describes the refractive state in which parallel light rays emanating from an object located 20 feet or more from the eye form a focused image on the retina of an eye that has not accommodated (",
"    <a class=\"graphic graphic_figure graphicRef81157 \" href=\"UTD.htm?20/26/20896\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef79812 \" href=\"UTD.htm?24/19/24894\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ametropia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ametropia (abnormal refraction) refers to the refractive state in which the image is not focused on the retina. Refractive disorders are ametropic states in which the eye is unable to bring light rays emanating from an object viewed from a distance into clear focus on the retina, without the aid of a refractive device (eg, spectacles, contact lenses). Myopia, hyperopia, and astigmatism are the three ametropic states. They are caused by abnormalities in the axial length of the eye or the shape of the cornea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Myopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopia (\"nearsightedness\") is a common refractive disorder in which the axial length of the eye is either too long (axial length is the distance from the posterior corneal surface to the retina) or the refractive power of the eye's optical system is too great (generally due to a steep cornea). The image is focused in front of the retina (",
"    <a class=\"graphic graphic_figure graphicRef65268 \" href=\"UTD.htm?25/23/25968\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef69617 \" href=\"UTD.htm?23/20/23886\">",
"     movie 2",
"    </a>",
"    ). This results in blurred distance vision unless optical correction is achieved with a refractive device. A refractive device can provide a more concave surface which reduces the excessive focusing power of the eye's optical system (",
"    <a class=\"graphic graphic_movie graphicRef80691 \" href=\"UTD.htm?40/2/41006\">",
"     movie 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyperopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperopia (\"farsightedness\") is a refractive disorder in which the axial length of the eye is too short or the power of the eye's optical system is insufficient (due to a flat cornea) to produce a focused image on the retina. The image is focused behind the retina (",
"    <a class=\"graphic graphic_figure graphicRef75265 \" href=\"UTD.htm?21/4/21568\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef72862 \" href=\"UTD.htm?30/37/31326\">",
"     movie 4",
"    </a>",
"    ). Hyperopia is corrected with a refractive device that provides a more convex refracting surface in order to increase the deficient focusing power of the eye's optical system (",
"    <a class=\"graphic graphic_movie graphicRef51690 \" href=\"UTD.htm?39/1/39966\">",
"     movie 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Astigmatism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Astigmatism (\"lack of a pinpoint\" in Greek) refers to the refractive condition in which a warped corneal surface causes light rays entering the eye along different planes to be focused unevenly (",
"    <a class=\"graphic graphic_movie graphicRef61074 \" href=\"UTD.htm?8/36/8783\">",
"     movie 6",
"    </a>",
"    ). The patient reports blurred vision at all viewing distances. Unlike myopia and hyperopia, which are corrected by spectacles containing a spherical surface, astigmatism is corrected by spectacles containing a cylindrical optical surface (",
"    <a class=\"graphic graphic_movie graphicRef68083 \" href=\"UTD.htm?13/28/13775\">",
"     movie 7",
"    </a>",
"    ). A spherical lens is a device with optical symmetry which can either converge or scatter light rays, while a cylindrical lens does not have optical symmetry. One meridian (a closed curve on the surface of a sphere) in the cylindrical lens is more curved than the opposite meridian. Soft (toric) or rigid gas permeable contact lenses can also be used to correct astigmatism. Contact lenses are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=see_link\">",
"     \"Overview of contact lenses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Presbyopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presbyopia (\"aging sight\") is a non-refractive error that also affects visual acuity. Presbyopia occurs when the lens loses its normal accommodating power and can no longer focus on objects viewed at arm's length or closer. As such, it is not considered an ametropic state, but rather one in which the normal physiologic function of lens accommodation has been lost.",
"   </p>",
"   <p>",
"    In youth, the eye is able to easily accommodate or increase the curvature of the lens by contracting the ciliary muscle (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 1",
"    </a>",
"    ). The ciliary muscle surrounds the lens and is connected to it by zonular fibers. The normally taut zonular fibers stretch the lens and keep it from assuming a fully rounded state. The desire to focus on reading material automatically stimulates ciliary smooth muscle contraction, which loosens the zonular fibers and allows the lens to become more rounded. In the fully rounded state, the lens provides the additional refractive power needed to bring reading material into focus.",
"   </p>",
"   <p>",
"    During the natural aging process, the crystalline lens loses its elasticity and therefore its ability to become more rounded when the zonular fibers loosen their grip. Presbyopia usually begins after age 40 when patients start to appreciate the inability to focus on objects at reading distance. In patients with presbyopia, the eye's focusing power for reading is lost progressively and fully by age 65 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The developing eye in childhood through early adulthood maintains focus on the retina by a process known as emmetropization. This process involves detection of a blurred image on the retina with subsequent diffusion of signals into the outer layers of the eye, including the choroid and sclera (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"     figure 1",
"    </a>",
"    ). This results in alteration of the size of the eye in order to maintain clear vision throughout development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/2\">",
"     2",
"    </a>",
"    ]. Emmetropization is accomplished by modulating scleral growth and choroidal thickness. With refractive errors, the emmetropization process goes awry for reasons that remain largely unknown.",
"   </p>",
"   <p>",
"    Cellular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physiologic mechanisms are thought to cause retinal defocusing with resulting altered axial length and myopia during the developmental process. In addition, eye growth is sensitive to an individual's visual experience. The mechanisms thought to cause retinal defocusing include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Form deprivation, which can lead to alterations in the ocular lens system, with elongation of the visual axis",
"     </li>",
"     <li>",
"      Excessive accommodation",
"     </li>",
"     <li>",
"      Scleral stretching (secondary to increased intraocular pressure)",
"     </li>",
"     <li>",
"      Autonomic deficits during accommodation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Animal models are being studied to delineate the role of neurotransmitters and hormones such as dopamine, VIP, acetylcholine, and glucagon in the signaling process by which the visual input of unfocused images on the retina can manipulate axial growth regulation processes during development [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence and risk factors associated with myopia are well-described. The epidemiologic data for other refractive errors has been less studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractive disorders are common, affecting approximately one third of persons age &ge;40 years in the United States (US) and Western Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, a total of 153 million people are estimated to be visually impaired from uncorrected refractive errors, of whom eight million are blind (as defined by best-corrected visual acuity",
"    <span class=\"nowrap\">",
"     &lt;20/400)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/8\">",
"     8",
"    </a>",
"    ]. The World Health Organization has introduced a global initiative for the elimination of avoidable blindness by the year 2020, with refractive error as one of the five conditions chosen as an immediate priority [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence rates vary depending on type of refractive error, with myopia and astigmatism being the most common. Hyperopia is uncommon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myopia &mdash; In the US, the prevalence of myopia from 1971-72 to 1999-2004 nearly doubled among persons age 12 to 54 years (25 versus 42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/10\">",
"       10",
"      </a>",
"      ]. This difference, in part, may reflect changes in education and consequent demands for close-up tasks such as reading, population shifts, and changes in the classification of myopia.",
"      <br/>",
"      <br/>",
"      Prevalence of myopia decreases with increasing age, from about 40 percent in adults age 20 to 59 years to about 20 percent in adults age &ge;60 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/11\">",
"       11",
"      </a>",
"      ]. In contrast to childhood-onset myopia where the degree of myopia tends to worsen rapidly, the degree of myopia stabilizes in late adolescence and is subject to a slow rate of myopic change after age 20.",
"      <br/>",
"      <br/>",
"      Prevalence rates of myopia also vary by race and ethnicity. In the US, Caucasians have the highest rates of myopia, followed by African-Americans, then Hispanic-Americans [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/11\">",
"       11",
"      </a>",
"      ]. Worldwide, the prevalence of myopia is especially high among Asians [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/8,12,13\">",
"       8,12,13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Development of myopia is also associated with higher education level, intelligence test scores, and occupations requiring close-up tasks of high accommodative demand (eg, reading, writing, computer work) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperopia &mdash; In contrast to myopia, the prevalence of hyperopia increases with age, from 1 to 2 percent in those age 20 to 59 years to 10 percent in those age &ge;60 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Astigmatism",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Similar to hyperopia, the prevalence of astigmatism increases with age from approximately 25 percent among adults age 20 to 59 to 50 percent among adults age &ge;60 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Presbyopia &mdash; Little epidemiologic data exists on presbyopia and lack of population-based studies prevents adequate assessment of its current prevalence [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/15\">",
"       15",
"      </a>",
"      ]. It is estimated that there were one billion people globally with presbyopia in 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/16\">",
"       16",
"      </a>",
"      ]. Approximately half had no spectacles or inadequate spectacles, and most of these had visual impairment that prevented them from performing close-up tasks. In the United States, presbyopia is the most common cause of visual impairment due to aging of the \"baby boomer\" generation, the 76 million Americans born between 1946 and 1964 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several different risk factors for myopia which have been well-documented [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/18-35\">",
"     18-35",
"    </a>",
"    ], whereas less data are available for other refractive errors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Myopia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic &mdash; Multiple studies have shown that hereditary factors are associated with the development of myopia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Lack of complete concordance between myopia and monozygotic twins, as well as between generations in families, suggests a polygenic inheritance model.",
"     </li>",
"     <li>",
"      Reading &mdash; An association between myopia and prolonged reading or reading at close range is well-documented [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Continuous hyperopic defocusing that occurs during prolonged periods of reading may lead the emmetropization mechanism to increase the axial length of the eye, leading to myopia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medications &mdash; Myopia can develop rapidly following use of certain medications. Sulfa-derived medications (eg, sulfamethoxazole,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ) and diuretics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ) can induce transient myopia through forward displacement and thickening of the lens by relaxation of the zonules [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/23\">",
"       23",
"      </a>",
"      ]. Cholinergic medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      ) can also result in accommodative spasm with subsequent transient myopia. Withdrawal of the medication usually results in complete resolution of myopia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diabetes mellitus &mdash; Refractive changes in patients with diabetes mellitus are well-documented [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Alterations in serum osmolarity secondary to changes in blood glucose levels can cause an influx of osmotic fluid into the lens with subsequent lens swelling and a transient increase in refractive power or myopia. As a result, patients with type I or type II diabetes often present with transient blurred vision, particularly those with poorly controlled glucose.",
"      <br/>",
"      <br/>",
"      The prevalence of myopia is higher in diabetic patients compared to non-diabetic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients with diabetes who have poorly controlled hemoglobin A1C are also more likely to have myopia.",
"     </li>",
"     <li>",
"      Trauma &mdash; Ocular trauma can cause forward displacement of the lens with subsequent myopia.",
"      <br/>",
"      <br/>",
"      Scleral laceration repair and use of scleral encircling elements in retinal detachment repair can temporarily deform the globe, inducing astigmatism and myopia. In cases where this deformation continues postoperatively, the increased axial length leads to persistent myopia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excessive accommodation &mdash; Patients with pathologically excessive accommodation may have \"accommodative spasm.\" The symptoms may include double vision and myopia. Anxiety and malingering (with forced excessive convergence by focusing on a near object) are common causes, but traumatic brain injury and parasympathomimetic medications can also lead to excessive accommodation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased intraocular pressure &mdash; Although the rate of myopia progression may be associated with increased intraocular pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/31\">",
"       31",
"      </a>",
"      ], data from the Correction of Myopia Evaluation Trial have shown no correlation between IOP and myopic progression [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cataract &mdash; As the accumulation of degenerated lens proteins continues and the opacification of the lens increases with a cataract, adequate visual acuity can no longer be restored even with correction of the myopia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"       \"Cataract in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maternal factors &mdash; Myopia is associated with greater maternal age at birth and maternal smoking during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other &mdash; Children who spend more time in outdoor activities have a lower prevalence of myopia, after correcting for time spent in near work [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results are mixed whether night lights (dim light left on during sleep) are associated with development of myopia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hyperopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors may lead to a posterior shift of the crystalline lens or shortening of the eye's axial length and result in hyperopia. These include trauma, mass effect of an orbital tumor posterior to the retina, scleral inflammation with subretinal thickening, and surgical removal of the crystalline lens without replacing it with a synthetic intraocular lens.",
"   </p>",
"   <p>",
"    Anticholinergic medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/59/10167?source=see_link\">",
"     oxybutynin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    ) exert parasympatholytic effects on the ciliary muscle, decreasing accommodation and inducing hyperopia. Patients treated for hyperglycemia who have a rapid decrease in blood glucose levels experience transient hyperopia that can last for several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Astigmatism &mdash; Risk factors for astigmatism are largely unknown, but may be related to genetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      developmental factors [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CLINICAL CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies have shown that refractive errors are associated with important clinical conditions, including limited physical function and ocular pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/40-48\">",
"     40-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one cohort study of noninstitutionalized elderly subjects, visual impairment was associated with limitations in instrumental activities of daily living (IADLs) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/40\">",
"     40",
"    </a>",
"    ]. The majority of subjects with visual impairment had uncorrected refractive error. It was estimated that one fifth of IADL limitations could be prevented by use of best optical correction.",
"   </p>",
"   <p>",
"    Patients with decreased vision are more likely to report a history of falls and hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/41\">",
"     41",
"    </a>",
"    ]. Those with impaired vision on detailed eye examination are also more likely to report a car accident within the last year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although visual correction may improve ability to read and perform other tasks, it does not appear to reduce risk or rate of falls among older adults. In one randomized trial, visual correction including new eyeglasses, glaucoma management, and cataract surgery led to an increased rate of falls compared to usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/49\">",
"     49",
"    </a>",
"    ], possibly related to an adjustment period needed to adapt to new corrective eyeglasses, and a less sedentary lifestyle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Associated eye disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;High degrees of refractive error (myopia &gt;6.0 D, hyperopia &gt;3.0 D, astigmatism &gt;3.0 D) are associated with pathologic ocular changes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Highly myopic patients have an increased incidence of retinal thinning, peripheral retinal degeneration, retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/44\">",
"     44",
"    </a>",
"    ], cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/45\">",
"     45",
"    </a>",
"    ], and glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Among patients with myopic refractive errors of 1 to 3 D, more than half of non-traumatic retinal detachments are attributable to myopia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=see_link\">",
"     \"Retinal detachment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=see_link\">",
"     \"Angle-closure glaucoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperopia is associated with ocular pathology, but to a lesser extent than myopia. Hyperopia is associated with angle closure glaucoma and age-related macular degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=see_link\">",
"     \"Age-related macular degeneration: Clinical presentation, etiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SCREENING AND DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on how and when to perform routine screening of visual acuity in the primary care setting. Different organizations have different recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Ophthalmology recommends comprehensive eye examinations by ophthalmologists for adults with no signs or risk factors as a baseline at age 40 years. Individuals without risk factors age 40 to 54 years should be examined every two to four years, those age 55 to 63 every one to three years, and those over 65 every one to two years. Any patient at higher risk for developing disease, based on ocular, medical, or family history should have periodic examinations determined by individual risk.",
"     </li>",
"     <li>",
"      The Canadian Task Force on the Periodic Health Examination recommends the Snellen eye chart be used for visual acuity during routine primary care visits for patients age 65 and older, although the frequency of testing is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The US Preventive Services Task Force states there is insufficient evidence to assess the benefits and harms of screening for impaired vision in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visual screening tests are recommended in children, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening tests in children and adolescents\", section on 'Vision screen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are a variety of visual charts to examine visual acuity, although little data is available showing superiority of one method over another [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/51\">",
"     51",
"    </a>",
"    ]. The Snellen eye chart is considered one of the clinical standards for evaluating visual acuity, and can be used in the primary care setting (",
"    <a class=\"graphic graphic_figure graphicRef50810 \" href=\"UTD.htm?14/10/14498\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2329/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients should have their vision examined at 20 feet and while reading (",
"    <a class=\"graphic graphic_figure graphicRef65268 \" href=\"UTD.htm?25/23/25968\">",
"     figure 3",
"    </a>",
"    ). While there is no explicit evidence regarding appropriate cutoffs for referral, patients with unexplained vision loss in either eye should be referred to an eye specialist for further evaluation.",
"   </p>",
"   <p>",
"    Although refractive errors may be suspected on history of visual blurriness or by visual acuity testing, diagnosis of all refractive disorders is confirmed with use of a phoropter by the eye specialist. A phoropter is an instrument containing different lenses used to bring the focus of objects onto the retina (",
"    <a class=\"graphic graphic_picture graphicRef66741 \" href=\"UTD.htm?9/57/10132\">",
"     picture 1",
"    </a>",
"    ). In addition to diagnosis, a phoropter is also used to measure severity of refractive error for prescribing corrective lenses.",
"   </p>",
"   <p>",
"    A retinoscope and pinhole occluder are additional devices that can be used to assess refractive error by an eye specialist. A retinoscope is an objective measure of refractive error that is not dependent upon patient response (",
"    <a class=\"graphic graphic_picture graphicRef55046 \" href=\"UTD.htm?12/50/13103\">",
"     picture 2",
"    </a>",
"    ). The retinoscope projects a beam of light into the patient's eye through the pupil. Through the peephole in the scope, the observer sees a light reflex coming from the patient's pupil. By observing the behavior of the reflex under certain conditions, the observer can objectively determine the refractive error of the patient's eye.",
"   </p>",
"   <p>",
"    A pinhole occluder may also be used as a screening tool for refractive errors (",
"    <a class=\"graphic graphic_picture graphicRef66325 \" href=\"UTD.htm?21/37/22111\">",
"     picture 3",
"    </a>",
"    ). The occluder is a simple way to focus light, as in a pinhole camera, temporarily removing the effects of refractive errors such as myopia. Because light passes only through the center of the eye's lens, defects in the shape of the lens (errors of refraction) have no effect while the occluder is used. This can allow estimation of the maximum improvement in a patient's vision that can be attained by lenses to correct errors of refraction. Squinting works similarly to a pinhole occluder, by blocking light through the outer parts of the eye's lens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat refractive disorders depends on the individual patient's symptoms and needs. Treatment is aimed to improve visual acuity, visual comfort, and other visual function (eg, color discrimination, motion detection, peripheral vision).",
"   </p>",
"   <p>",
"    First-line treatments include corrective lenses, such as glasses and contact lenses, or refractive surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Corrective lenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corrective lenses work by altering the overall power of the lens system of the eye. Concave lenses for myopia act to weaken the lens system, or reduce its power in diopters. Convex lenses for hyperopia act by strengthening the lens system, or increasing its power in diopters. Cylindrical lenses are used to correct astigmatism.",
"   </p>",
"   <p>",
"    Presbyopia is treated with use of convex lenses as \"reading glasses\" or in combination with a correction for distance viewing in which the lenses may be lined (bifocals, trifocals) or unlined (multifocals, progressive).",
"   </p>",
"   <p>",
"    Spectacles, or glasses, are the most common method of treating refractive errors, followed by contact lenses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=see_link\">",
"     \"Overview of contact lenses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Interpreting the prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;By convention, lenses that increase divergence and decrease the eye's focusing power are considered \"minus\" lenses; lenses that increase convergence and increase focusing power are considered \"plus\" lenses. Accordingly, myopic refractive error is corrected with concave (\"minus\", \"divergent\") lenses (",
"    <a class=\"graphic graphic_movie graphicRef80691 \" href=\"UTD.htm?40/2/41006\">",
"     movie 3",
"    </a>",
"    ), and hyperopia is corrected with convex (\"plus\", \"convergent\") lenses (",
"    <a class=\"graphic graphic_movie graphicRef51690 \" href=\"UTD.htm?39/1/39966\">",
"     movie 5",
"    </a>",
"    ). Astigmatism is corrected by cylindrical lenses which even out the eye's focusing power (",
"    <a class=\"graphic graphic_movie graphicRef68083 \" href=\"UTD.htm?13/28/13775\">",
"     movie 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In spectacle prescription notation, the first number is the refractive power, also known as the sphere. A minus number indicates a concave lens; a plus number indicates a convex lens. The second number denotes the cylinder, which corrects any astigmatic component. The \"x\" that follows the astigmatism power denotes the axis (in radial degrees) of the cylinder. Spectacle prescriptions are then written in increments of 0.25 D. For example, a prescription for a patient with myopia and astigmatism may read -4.50 + 2.50 x 090 and a prescription for a patient with hyperopia and astigmatism may read +3.25 + 1.50 x 180.",
"   </p>",
"   <p>",
"    OD signifies the right eye (oculus dexter in Latin). OS signifies the left eye (oculus sinister). OU signifies both eyes (oculi uterque).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgical correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common surgical procedure performed to correct refractive errors is laser in situ keratomileusis (LASIK). Overall outcomes with LASIK are favorable, leading to rapid recovery of vision and minimal pain after surgery. Other corneal surgical procedures include photorefractive keratectomy (PRK), and laser epithelial keratomileusis (LASEK). Laser refractive procedures are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=see_link\">",
"     \"Laser refractive surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraocular lens implants, similar to those used to correct vision with cataract surgery, can correct high degrees of myopia. However, intraocular lens implants can result in cataract formation, increased intraocular pressure, and damage to the cornea over time. Thus, lens implants are not routinely recommended for correction of refractive errors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       \"Patient information: Age-related vision loss (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=see_link\">",
"       \"Patient information: Glaucoma (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/6/28769?source=see_link\">",
"       \"Patient information: Presbyopia and refractive errors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Refractive errors occur when a component of the eye's optical system fails to focus an optical image onto the retina. The optical system consists of two refractive surfaces working in tandem: the cornea and the crystalline lens (",
"      <a class=\"graphic graphic_figure graphicRef59910 \" href=\"UTD.htm?2/6/2150\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functional anatomy of the eye'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refractive errors include myopia (nearsightedness), hyperopia (farsightedness), and astigmatism (abnormal corneal shape). Presbyopia (aging sight) is a non-refractive error that occurs when the lens loses its normal accommodating power. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in refraction are common, affecting one-third of persons age &ge;40 years in the United States and Western Europe. Worldwide, uncorrected refractive errors are a common cause of poor visual acuity and blindness. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of visual acuity in the primary care setting can be performed with a standard Snellen chart. Patients with visual acuity less than",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"      in either eye have impaired visual acuity and should be referred to an eye specialist for further evaluation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Screening and diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatments for refractive errors include glasses, contact lenses, and refractive surgery. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=see_link\">",
"       \"Laser refractive surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Subcommittee AAoOBaCS. Section 3: Clinical Optics. San Francisco, CA: American Academy of Ophthalmology, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/2\">",
"      Lawrence MS, Azar DT. Myopia and models and mechanisms of refractive error control. Ophthalmol Clin North Am 2002; 15:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/3\">",
"      Wallman J, Winawer J. Homeostasis of eye growth and the question of myopia. Neuron 2004; 43:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/4\">",
"      Chen JC, Schmid KL, Brown B. The autonomic control of accommodation and implications for human myopia development: a review. Ophthalmic Physiol Opt 2003; 23:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/5\">",
"      McCarthy CS, Megaw P, Devadas M, Morgan IG. Dopaminergic agents affect the ability of brief periods of normal vision to prevent form-deprivation myopia. Exp Eye Res 2007; 84:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/6\">",
"      Rymer J, Wildsoet CF. The role of the retinal pigment epithelium in eye growth regulation and myopia: a review. Vis Neurosci 2005; 22:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/7\">",
"      Kempen JH, Mitchell P, Lee KE, et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol 2004; 122:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/8\">",
"      Resnikoff S, Pascolini D, Mariotti SP, Pokharel GP. Global magnitude of visual impairment caused by uncorrected refractive errors in 2004. Bull World Health Organ 2008; 86:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/9\">",
"      McCarty CA, Taylor HR. Myopia and vision 2020. Am J Ophthalmol 2000; 129:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/10\">",
"      Vitale S, Sperduto RD, Ferris FL 3rd. Increased prevalence of myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009; 127:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/11\">",
"      Vitale S, Ellwein L, Cotch MF, et al. Prevalence of refractive error in the United States, 1999-2004. Arch Ophthalmol 2008; 126:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/12\">",
"      McCarty CA, Livingston PM, Taylor HR. Prevalence of myopia in adults: implications for refractive surgeons. J Refract Surg 1997; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/13\">",
"      Krishnaiah S, Srinivas M, Khanna RC, Rao GN. Prevalence and risk factors for refractive errors in the South Indian adult population: The Andhra Pradesh Eye disease study. Clin Ophthalmol 2009; 3:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/14\">",
"      Saw SM, Katz J, Schein OD, et al. Epidemiology of myopia. Epidemiol Rev 1996; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/15\">",
"      Weale RA. Epidemiology of refractive errors and presbyopia. Surv Ophthalmol 2003; 48:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/16\">",
"      Holden BA, Fricke TR, Ho SM, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol 2008; 126:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/17\">",
"      Rosenbloom AA Jr. New aged and old aged: impact of the Baby Boomer. Optometry 2003; 74:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/18\">",
"      Dirani M, Chamberlain M, Shekar SN, et al. Heritability of refractive error and ocular biometrics: the Genes in Myopia (GEM) twin study. Invest Ophthalmol Vis Sci 2006; 47:4756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/19\">",
"      Dirani M, Shekar SN, Baird PN. Evidence of shared genes in refraction and axial length: the Genes in Myopia (GEM) twin study. Invest Ophthalmol Vis Sci 2008; 49:4336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/20\">",
"      Saw SM, Chua WH, Hong CY, et al. Nearwork in early-onset myopia. Invest Ophthalmol Vis Sci 2002; 43:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/21\">",
"      Ip JM, Saw SM, Rose KA, et al. Role of near work in myopia: findings in a sample of Australian school children. Invest Ophthalmol Vis Sci 2008; 49:2903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/22\">",
"      Mutti DO, Mitchell GL, Hayes JR, et al. Accommodative lag before and after the onset of myopia. Invest Ophthalmol Vis Sci 2006; 47:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/23\">",
"      Bovino JA, Marcus DF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol 1982; 94:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/24\">",
"      Drug-induced myopia. Prescrire Int 2003; 12:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/25\">",
"      Duke-Elder WS. CHANGES IN REFRACTION IN DIABETES MELLITUS. Br J Ophthalmol 1925; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/26\">",
"      Fledelius HC, Fuchs J, Reck A. Refraction in diabetics during metabolic dysregulation, acute or chronic. With special reference to the diabetic myopia concept. Acta Ophthalmol (Copenh) 1990; 68:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/27\">",
"      Jacobsen N, Jensen H, Lund-Andersen H, Goldschmidt E. Is poor glycaemic control in diabetic patients a risk factor of myopia? Acta Ophthalmol 2008; 86:510.",
"     </a>",
"    </li>",
"    <li>",
"     Trobe JD. Symptoms of Optical Disorders. In: Neurology of Vision, 1st ed, Oxford University Press, New York 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/29\">",
"      Goldstein JH, Schneekloth BB. Spasm of the near reflex: a spectrum of anomalies. Surv Ophthalmol 1996; 40:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/30\">",
"      Tijssen CC, Goor C, Van Woerkom TC. Spasm of the near reflex: functional or organic disorder. Neuro-ophthalmology 1983; 3:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/31\">",
"      Mitchell P, Hourihan F, Sandbach J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. Ophthalmology 1999; 106:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/32\">",
"      Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol 1983; 118:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/33\">",
"      Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology 2008; 115:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/34\">",
"      Saw SM, Wu HM, Hong CY, et al. Myopia and night lighting in children in Singapore. Br J Ophthalmol 2001; 85:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/35\">",
"      Saw SM, Zhang MZ, Hong RZ, et al. Near-work activity, night-lights, and myopia in the Singapore-China study. Arch Ophthalmol 2002; 120:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/36\">",
"      Furushima M, Imaizumi M, Nakatsuka K. Changes in refraction caused by induction of acute hyperglycemia in healthy volunteers. Jpn J Ophthalmol 1999; 43:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/37\">",
"      Lin SF, Lin PK, Chang FL, Tsai RK. Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed diabetes. Ophthalmologica 2009; 223:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/38\">",
"      Read SA, Collins MJ, Carney LG. A review of astigmatism and its possible genesis. Clin Exp Optom 2007; 90:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/39\">",
"      Rahi JS, Cumberland PM, Peckham CS. Myopia over the lifecourse: prevalence and early life influences in the 1958 British birth cohort. Ophthalmology 2011; 118:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/40\">",
"      Daien V, P&eacute;r&egrave;s K, Villain M, et al. Visual impairment, optical correction, and their impact on activity limitations in elderly persons: the POLA study. Arch Intern Med 2011; 171:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/41\">",
"      Klein BE, Klein R, Lee KE, Cruickshanks KJ. Performance-based and self-assessed measures of visual function as related to history of falls, hip fractures, and measured gait time. The Beaver Dam Eye Study. Ophthalmology 1998; 105:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/42\">",
"      Ivers RQ, Mitchell P, Cumming RG. Sensory impairment and driving: the Blue Mountains Eye Study. Am J Public Health 1999; 89:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/43\">",
"      Saw SM, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated pathological complications. Ophthalmic Physiol Opt 2005; 25:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/44\">",
"      Risk factors for idiopathic rhegmatogenous retinal detachment. The Eye Disease Case-Control Study Group. Am J Epidemiol 1993; 137:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/45\">",
"      Lim R, Mitchell P, Cumming RG. Refractive associations with cataract: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 1999; 40:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/46\">",
"      Gr&oslash;dum K, Heijl A, Bengtsson B. Refractive error and glaucoma. Acta Ophthalmol Scand 2001; 79:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/47\">",
"      Wong TY, Klein BE, Klein R, et al. Refractive errors, intraocular pressure, and glaucoma in a white population. Ophthalmology 2003; 110:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/48\">",
"      Ikram MK, van Leeuwen R, Vingerling JR, et al. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003; 44:3778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/49\">",
"      Cumming RG, Ivers R, Clemson L, et al. Improving vision to prevent falls in frail older people: a randomized trial. J Am Geriatr Soc 2007; 55:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/50\">",
"      Periodic health examination, 1995 update: 3. Screening for visual problems among elderly patients. Canadian Task Force on the Periodic Health Examination. CMAJ 1995; 152:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/51\">",
"      Chou R, Dana T, Bougatsos C. Screening older adults for impaired visual acuity: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2329/abstract/52\">",
"      Kniestedt C, Stamper RL. Visual acuity and its measurement. Ophthalmol Clin North Am 2003; 16:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6895 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2329=[""].join("\n");
var outline_f2_17_2329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONAL ANATOMY OF THE EYE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Emmetropia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ametropia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Myopia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyperopia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Astigmatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Presbyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Myopia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hyperopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CLINICAL CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Associated eye disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SCREENING AND DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Corrective lenses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Interpreting the prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgical correction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6895\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6895|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/6/2150\" title=\"figure 1\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/26/20896\" title=\"figure 2\">",
"      Normal vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/23/25968\" title=\"figure 3\">",
"      Myopia steep cornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/4/21568\" title=\"figure 4\">",
"      Hyperopia flat cornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/10/14498\" title=\"figure 5\">",
"      Snellen chart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6895|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/57/10132\" title=\"picture 1\">",
"      Phoropter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/50/13103\" title=\"picture 2\">",
"      Retinoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/37/22111\" title=\"picture 3\">",
"      Pinhole occluder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6895|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?24/19/24894\" title=\"movie 1\">",
"      Emmetropia normal refraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?23/20/23886\" title=\"movie 2\">",
"      Myopia nearsightedness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/2/41006\" title=\"movie 3\">",
"      Correction of myopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/37/31326\" title=\"movie 4\">",
"      Hyperopia farsightedness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?39/1/39966\" title=\"movie 5\">",
"      Correction of hyperopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/36/8783\" title=\"movie 6\">",
"      Astigmatism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?13/28/13775\" title=\"movie 7\">",
"      Correction of astigmatism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/52/6986?source=related_link\">",
"      Age-related macular degeneration: Clinical presentation, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9063?source=related_link\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=related_link\">",
"      Laser refractive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18183?source=related_link\">",
"      Overview of contact lenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/6/28769?source=related_link\">",
"      Patient information: Presbyopia and refractive errors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2330="Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis";
var content_f2_17_2330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/17/2330/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/17/2330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure is characterized by acute liver injury, hepatic encephalopathy, and a prolonged prothrombin time. It has also been referred to as fulminant hepatic failure, acute hepatic necrosis, fulminant hepatic necrosis, and fulminant hepatitis. Untreated, the prognosis is poor, so timely recognition and management of patients with acute liver failure is crucial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/1\">",
"     1",
"    </a>",
"    ]. Whenever possible, patients with acute liver failure should be managed in an intensive care unit at a facility capable of performing liver transplantation.",
"   </p>",
"   <p>",
"    This topic will review the etiology, clinical manifestations, and diagnosis of acute liver failure in adults. The prognosis and management of patients with acute liver failure is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion that follows is consistent with the 2011 The American Association for the Study of Liver Diseases (AASLD)",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf\">",
"     guideline",
"    </a>",
"    for the management of acute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73465368\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure refers to the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio [INR] of &ge;1.5) in a patient without cirrhosis or preexisting liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. While the time course that differentiates acute liver failure from chronic liver failure varies between reports, a commonly used cut-off is an illness duration of &lt;26 weeks.",
"   </p>",
"   <p>",
"    Acute liver failure may also be diagnosed in patients with previously undiagnosed Wilson disease, vertically-acquired hepatitis B virus, or autoimmune hepatitis, in whom underlying cirrhosis may be present, provided the disease has been recognized for &lt;26 weeks. On the other hand, patients with acute severe alcoholic hepatitis, even if recognized for &lt;26 weeks, are considered to have acute-on-chronic liver failure since most have a long history of heavy drinking. The approach to such patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute liver failure can be subcategorized based upon how long the patient has been ill and various cutoffs have been used. We classify acute liver failure as hyperacute (&lt;7 days), acute (7 to 21 days), or (subacute &gt;21 days and &lt;26 weeks). In patients with hyperacute or acute liver failure, cerebral edema is common, whereas it is rare in subacute liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/4\">",
"     4",
"    </a>",
"    ]. On the other hand, renal failure and portal hypertension are more frequently observed in patients with subacute liver failure. These subcategories have been associated with prognosis, but the associations reflect the underlying causes, which are the true determinants of prognosis. As an example, patients with hyperacute liver failure tend to have a better prognosis than those with subacute liver failure. The better prognosis is related to the fact that these patients often have",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity or ischemic hepatopathy, diagnoses associated with a better prognosis than many of the disorders that may result in subacute liver failure, such as Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure can result from a wide variety of causes, including (",
"    <a class=\"graphic graphic_table graphicRef67925 \" href=\"UTD.htm?24/16/24843\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79913 \" href=\"UTD.htm?43/1/44060\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen (paracetamol)",
"      </a>",
"     </li>",
"     <li>",
"      Idiosyncratic drug reactions",
"     </li>",
"     <li>",
"      Viral hepatitis",
"     </li>",
"     <li>",
"      Alcoholic hepatitis",
"     </li>",
"     <li>",
"      Autoimmune hepatitis",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Ischemic hepatopathy",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome",
"     </li>",
"     <li>",
"      Veno-occlusive disease",
"     </li>",
"     <li>",
"      Acute fatty liver of",
"      <span class=\"nowrap\">",
"       pregnancy/HELLP",
"      </span>",
"      (hemolysis, elevated liver enzymes, low platelets) syndrome",
"     </li>",
"     <li>",
"      Malignant infiltration (most often breast cancer, small cell lung cancer, lymphoma, melanoma, or myeloma)",
"     </li>",
"     <li>",
"      Partial hepatectomy",
"     </li>",
"     <li>",
"      Toxin exposure, including mushroom poisoning",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Heat stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral and drug-induced hepatitis are the most common causes of acute liver failure in adults. In Australia, Denmark, the United Kingdom, and the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    is the most common cause of acute liver failure, whereas in Asia and some other parts of Europe, viral hepatitis predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the US Acute Liver Failure Study Group collected data on 1147 cases of acute liver failure from 23 sites between 1998 and 2007 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/1\">",
"       1",
"      </a>",
"      ]. The most common causes of acute liver failure were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      overdose (46 percent), indeterminate (14 percent), idiosyncratic drug reactions (12 percent), hepatitis B virus (7 percent), and hepatitis A virus (3 percent).",
"     </li>",
"     <li>",
"      Among 1014 patients with acute liver failure referred to King's College Hospital in the United Kingdom between 1973 and 1991, 57 percent were",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      -induced, and 9 percent were attributable to hepatitis B or D [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 502 patients with acute liver failure referred to the Hospital Beaujon in France between 1972 and 1990, 45 percent of the cases were related to hepatitis B or D, and 2 percent were attributable to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 856 patients with acute liver failure in Japan between 1998 and 2006, 51 percent of cases were due to viral hepatitis (42 percent hepatitis B), and 10 percent were due to drugs (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several viruses have been associated with acute liver failure, including hepatitis A, B, C, D, and E. In addition, acute liver failure can be seen with herpes simplex virus, varicella zoster virus, Epstein-Barr virus, adenovirus, and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/1,6\">",
"     1,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute liver failure is estimated to develop in 0.35 percent of patients with hepatitis A and in 0.1 to 0.5 percent of patients with acute hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the incidence of acute liver failure from hepatitis B may be underestimated. Precore or pre-S mutant hepatitis B viruses that are able to produce infection but do not produce hepatitis B surface antigen or e antigen may be difficult to diagnose by routine serology. Thus, liver failure in such patients may be erroneously attributed to cryptogenic causes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/10\">",
"     10",
"    </a>",
"    ]. This was illustrated in a study in which evidence of hepatitis B infection was detected by polymerase chain reaction (PCR) in 6 of 17 patients (35 percent) who underwent liver transplantation for what was initially thought to be non-A, non-B hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Acute hepatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=see_link\">",
"     \"Clinical significance and molecular characteristics of common hepatitis B virus variants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to acute hepatitis B, acute liver failure may also develop in patients who are receiving chemotherapy or immunosuppression and have reactivation of previously inactive hepatitis B. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatitis C virus alone does not appear to be a significant cause of acute liver failure in the absence of coinfection with hepatitis B. In a study of 109 patients with acute hepatitis C, acute liver failure developed in 11 (10 percent), 9 of whom had concurrent hepatitis B infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with hepatitis D virus can lead to acute liver failure in patients with hepatitis B virus infection. A patient may either acquire both viruses at the same time (coinfection) or acquire hepatitis D in the setting of preexisting chronic hepatitis B (superinfection). The risk of acute liver failure appears to be higher among patients who are coinfected than in those with hepatitis D superinfection or with acute hepatitis B alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=see_link\">",
"     \"Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatitis E virus is a significant cause of liver failure in countries where it is endemic, such as Russia, Pakistan, Mexico, and India. Overall, the case-fatality rate for hepatitis E is 0.5 to 3 percent. However, among women who are pregnant, the mortality rate increases to 15 to 25 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link&amp;anchor=H5#H5\">",
"     \"Hepatitis E virus infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acetaminophen and other hepatotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is the most common toxin associated with acute liver failure in the United States and other developed countries (",
"    <a class=\"graphic graphic_table graphicRef79913 \" href=\"UTD.htm?43/1/44060\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"     5",
"    </a>",
"    ]. The hepatotoxicity is dose-dependent and rarely occurs at therapeutic doses (up to four grams per day in a patient without preexisting liver disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases occur after ingestion of large doses in an attempt to commit suicide. In addition, some patients unknowingly take large amounts of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    when multiple acetaminophen-containing medications are taken together or if acetaminophen-containing medications are not taken as directed (a \"therapeutic misadventure\"). Acute liver failure can also result from normally therapeutic doses in patients who have underlying liver disease (particularly with ongoing alcohol use, which induces the cytochrome P450 system) or who are taking medications known to induce the cytochrome P450 system (particularly CYP2E1), such as anticonvulsants (",
"    <a class=\"graphic graphic_figure graphicRef68213 \" href=\"UTD.htm?20/49/21279\">",
"     figure 1",
"    </a>",
"    ) .",
"   </p>",
"   <p>",
"    Other toxins associated with acute liver failure include mushroom poisoning (most often",
"    <em>",
"     Amanita phalloides",
"    </em>",
"    ) and carbon tetrachloride. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10698?source=see_link\">",
"     \"Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27736?source=see_link&amp;anchor=H7#H7\">",
"     \"Hydrocarbon poisoning\", section on 'Acute systemic toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64479183\">",
"    <span class=\"h2\">",
"     Idiosyncratic drug reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike acute liver failure due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , which is dose-related, acute liver failure due to idiosyncratic drug reactions (known as drug-induced liver injury [DILI]) is dose-independent. DILI usually occurs within six months of drug initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ]. Drugs commonly implicated in cases of DILI include antibiotics, nonsteroidal anti-inflammatory drugs, and anticonvulsants (",
"    <a class=\"graphic graphic_table graphicRef79913 \" href=\"UTD.htm?43/1/44060\">",
"     table 2",
"    </a>",
"    ). Herbal medications and dietary supplements have also been associated with acute liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64480066\">",
"    <span class=\"h2\">",
"     Hypoperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoperfusion of the liver can result in ischemic hepatitis and acute liver failure. Hypoperfusion may result from systemic hypotension due to causes such as cardiac dysfunction, sepsis, or drugs. Hypoperfusion of the liver may also be seen with Budd-Chiari syndrome (hepatic vein thrombosis), veno-occlusive disease, or the use of vasoconstricting drugs such as cocaine and methamphetamine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link\">",
"     \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64480073\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with acute liver failure have severe acute liver injury (demonstrated by liver test abnormalities) with signs of hepatic encephalopathy and a prolonged prothrombin time (INR &ge;1.5). Other clinical manifestations may include jaundice, hepatomegaly, and right upper quadrant tenderness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76739483\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the initial symptoms in patients with acute liver failure are nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/13\">",
"     13",
"    </a>",
"    ]. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Fatigue/malaise",
"      </span>",
"     </li>",
"     <li>",
"      Lethargy",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting",
"     </li>",
"     <li>",
"      Right upper quadrant pain",
"     </li>",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Jaundice",
"     </li>",
"     <li>",
"      Abdominal distension from ascites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the liver failure progresses, patients who were initially anicteric may develop jaundice, and those with subtle mental status changes (eg, lethargy, difficulty sleeping) may become confused or eventually comatose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165773354\">",
"    <span class=\"h2\">",
"     Physical examination findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73466383\">",
"    <span class=\"h3\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of hepatic encephalopathy is one of the defining characteristics of acute liver failure. Findings in patients with hepatic encephalopathy are variable, ranging from changes in behavior to coma. Hepatic encephalopathy is graded from I to IV (",
"    <a class=\"graphic graphic_table graphicRef62922 \" href=\"UTD.htm?32/17/33051\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70740 \" href=\"UTD.htm?12/37/12883\">",
"     figure 2",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I: Changes in behavior, mild confusion, slurred speech, disordered sleep",
"     </li>",
"     <li>",
"      Grade II: Lethargy, moderate confusion",
"     </li>",
"     <li>",
"      Grade III: Marked confusion (stupor), incoherent speech, sleeping but wakes with stimulation",
"     </li>",
"     <li>",
"      Grade IV: Coma, unresponsive to pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with grade I encephalopathy may have mild asterixis, whereas pronounced asterixis is typically seen in patients with grade II or III encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"     5",
"    </a>",
"    ]. Asterixis is typically absent in patients with grade IV encephalopathy, who instead may demonstrate decorticate or decerebrate posturing.",
"   </p>",
"   <p>",
"    Cerebral edema may develop in patients with acute liver failure leading to increased intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"     5",
"    </a>",
"    ]. Cerebral edema is uncommon in patients with grade I or II encephalopathy, but it is present in 25 to 35 percent of those with grade III encephalopathy and in approximately 75 percent of those with grade IV encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Pupillary changes are one sign of increased intracranial pressure. The pupils may progress from having a normal response (typical with grade I encephalopathy), to being hyperresponsive (grade II to III encephalopathy), to being slowly responsive (grade III to IV encephalopathy). As the coma worsens, the pupils may become fixed and dilated (a sign typically associated with brainstem herniation).",
"   </p>",
"   <p>",
"    Other clinical features of increased intracranial pressure include systemic hypertension, bradycardia, respiratory depression (Cushing's triad), seizures, and paralysis of other brain stem reflexes (eg, oculocephalic reflex, corneal reflex, jaw reflex, cough response to tracheobronchial suctioning). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seizure activity in patients with acute liver failure is common, but may be difficult to detect if patients are intubated and receiving paralytics. In the control arm of one trial, 7 of 22 patients (32 percent) had subclinical seizure activity detected by electroencephalogram [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73466390\">",
"    <span class=\"h3\">",
"     Other physical examination findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other findings on physical examination in patients with acute liver failure may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jaundice, which is a common finding in patients with acute liver failure but may be absent early in the course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      poisoning or herpes simplex virus infection [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vesicular skin lesions suggestive of herpes simplex virus (present in 30 to 50 percent of patients with acute liver failure due to herpes simplex virus) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2,16\">",
"       2,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fever in patients with herpes simplex virus (reported in 82 percent of patients in one review) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Right upper quadrant tenderness and hepatomegaly",
"     </li>",
"     <li>",
"      Ascites",
"     </li>",
"     <li>",
"      Signs of intravascular volume depletion, such as orthostatic hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607198\">",
"    <span class=\"h2\">",
"     Laboratory test abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory test abnormalities typically seen in patients with acute liver failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged prothrombin time, resulting in an INR &ge;1.5 (this finding is part of the definition of acute liver failure and thus must be present)",
"     </li>",
"     <li>",
"      Elevated aminotransferase levels (often markedly elevated)",
"     </li>",
"     <li>",
"      Elevated bilirubin level",
"     </li>",
"     <li>",
"      Low platelet count",
"      <span class=\"nowrap\">",
"       (&le;150,000/mm",
"       <sup>",
"        3",
"       </sup>",
"       ,",
"      </span>",
"      though hemostasis when measured by thromboelastography is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/17,18\">",
"       17,18",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decreasing aminotransferase levels may indicate spontaneous recovery but could also signal worsening of the liver failure with loss of hepatocyte mass. In patients who are improving, the bilirubin and prothrombin time will decline, whereas in those with worsening liver failure, the bilirubin and prothrombin time will continue to rise. Because of the prognostic importance of the prothrombin time, it is recommended that coagulation factors such as fresh frozen plasma only be given for invasive procedures or active bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, despite an abnormal INR, patients may not be hypocoagulable. In a study of 20 patients with acute liver failure, thromboelastography suggested a hypocoagulable state in 20 percent, normal coagulation in 45 percent, and a hypercoagulable state in 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H166750581#H166750581\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Bleeding prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory findings that may be seen in patients with acute liver failure include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated serum creatinine and blood urea nitrogen",
"     </li>",
"     <li>",
"      Elevated amylase and lipase",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Hypophosphatemia",
"     </li>",
"     <li>",
"      Hypomagnesemia",
"     </li>",
"     <li>",
"      Hypokalemia",
"     </li>",
"     <li>",
"      Acidosis or alkalosis",
"     </li>",
"     <li>",
"      Elevated ammonia level",
"     </li>",
"     <li>",
"      Elevated lactate dehydrogenase (LDH) level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute renal failure complicates acute liver failure in approximately 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/14,20,21\">",
"     14,20,21",
"    </a>",
"    ]. The frequency of acute renal failure is higher (up to 75 percent) for etiologies of acute liver failure that are known to independently damage the kidneys, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/10,22\">",
"     10,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of renal failure in patients with acute liver failure is incompletely understood but may be related to systemic and intrarenal hemodynamic changes similar to those seen in hepatorenal syndrome. The clinical picture is similar in that the urine sodium concentration and fractional excretion are very low in the absence of diuretic therapy or tubular injury (as might be induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ), and the urine sediment shows few or no cells or casts in the absence of marked hyperbilirubinemia. The blood urea nitrogen concentration may not be a sensitive test to follow renal function in patients with acute liver failure since hepatic production of urea is decreased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=see_link\">",
"     \"Hepatorenal syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55634786\">",
"    <span class=\"h3\">",
"     Laboratory findings associated with specific diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory test findings often vary depending upon the specific cause of the acute liver failure. Patterns seen on laboratory testing may suggest a diagnosis, but additional laboratory and imaging testing is required prior to making a diagnosis. These patterns should not be used to rule in or rule out a given diagnosis. (See",
"    <a class=\"local\" href=\"#H64480080\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patterns that may be seen include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      : Very high aminotransferase levels (&gt;3500 int.",
"      <span class=\"nowrap\">",
"       unit/L),",
"      </span>",
"      low bilirubin, high INR (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link&amp;anchor=H18#H18\">",
"       \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ischemic hepatic injury: Very high aminotransferase levels (25 to 250 times the upper limit of normal), elevated serum LDH levels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=see_link&amp;anchor=H3#H3\">",
"       \"Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hepatitis B: Aminotransferase levels of to 1000 to 2000 int.",
"      <span class=\"nowrap\">",
"       unit/L",
"      </span>",
"      are common, alanine aminotransferase (ALT) level that is higher than the aspartate aminotransferase (AST) level (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and natural history of hepatitis B virus infection\", section on 'Acute hepatitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wilson disease: Coombs-negative hemolytic anemia, aminotransferase levels &lt;2000 int.",
"      <span class=\"nowrap\">",
"       unit/L,",
"      </span>",
"      AST to ALT ratio of &gt;2, normal or markedly subnormal alkaline phosphatase (&lt;40 int.",
"      <span class=\"nowrap\">",
"       unit/L),",
"      </span>",
"      alkaline phosphatase (int.",
"      <span class=\"nowrap\">",
"       unit/L)",
"      </span>",
"      to total bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)",
"      </span>",
"      ratio &lt;4, rapidly progressive renal failure, low uric acid levels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69501971#H69501971\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Acute hepatitis and acute liver failure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute fatty liver of",
"      <span class=\"nowrap\">",
"       pregnancy/HELLP",
"      </span>",
"      syndrome: Aminotransferase levels &lt;1000 int.",
"      <span class=\"nowrap\">",
"       unit/L,",
"      </span>",
"      elevated bilirubin, low platelet count (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link&amp;anchor=H3#H3\">",
"       \"Acute fatty liver of pregnancy\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Herpes simplex virus: Markedly elevated transaminases, leukopenia, low bilirubin",
"     </li>",
"     <li>",
"      Reye syndrome,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      toxicity, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      toxicity: Minor to moderate elevations in aminotransferase and bilirubin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607206\">",
"    <span class=\"h2\">",
"     Imaging and other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal computed tomography (CT) in a patient with acute liver failure often reveals a liver that appears less dense than skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/23\">",
"     23",
"    </a>",
"    ]. Other findings may include heterogenous liver parenchyma, hepatomegaly, ascites, evidence of malignant infiltration, and evidence of hepatic vein occlusion. Cirrhosis may be present in patients with acute liver failure due to Wilson disease, vertically-transmitted hepatitis B, or autoimmune hepatitis and may result in a nodular-appearing liver on imaging. However, a massively necrotic liver may also appear nodular due to parenchymal collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/24\">",
"     24",
"    </a>",
"    ]. However, because of the risk of renal failure with the intravenous contrast used for CT, ultrasound with Doppler imaging is often preferred for the evaluation of acute liver failure. (See",
"    <a class=\"local\" href=\"#H414607145\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Neuroimaging (head CT or magnetic resonance imaging) in patients with acute liver failure may reveal evidence of cerebral edema, including a decrease in the size of the ventricles, flattening of cerebral convolutions, and attenuation of the signal intensity of brain parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/25\">",
"     25",
"    </a>",
"    ]. An electroencephalogram may reveal seizure activity, even in the absence of clinical signs of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary edema and pulmonary infections develop in approximately 30 percent of patients with acute liver failure and may be seen on chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Pulmonary edema'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64480080\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63223121\">",
"    <span class=\"h2\">",
"     Diagnosing acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute liver failure should be in the differential diagnosis of patients with the recent onset (&lt;26 weeks) of mental status changes, jaundice, or right upper quadrant pain. It should also be considered in patients with nonspecific symptoms such as nausea, vomiting, and malaise. The evaluation of such patients should include serum liver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transpeptidase [GGT], total and direct bilirubin, albumin). If the liver tests are abnormal, the patient's prothrombin time should also be measured. (See",
"    <a class=\"local\" href=\"#H76739483\">",
"     'Symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acute liver failure is diagnosed by demonstrating all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated aminotransferases (often with abnormal bilirubin and alkaline phosphatase levels) (see",
"      <a class=\"local\" href=\"#H414607198\">",
"       'Laboratory test abnormalities'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hepatic encephalopathy (see",
"      <a class=\"local\" href=\"#H73466383\">",
"       'Neurologic examination'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Prolonged prothrombin time (INR &ge;1.5) (see",
"      <a class=\"local\" href=\"#H414607198\">",
"       'Laboratory test abnormalities'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63223030\">",
"    <span class=\"h2\">",
"     Determining the cause of acute liver failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cause for acute liver failure can be established in approximately 60 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/4\">",
"     4",
"    </a>",
"    ]. Identifying the underlying cause of the liver failure is important because it influences the approach to management and provides prognostic information. A diagnosis is typically made with a combination of history taking, laboratory tests, and imaging studies. If the initial evaluation fails to identify an etiology, a liver biopsy may be required.",
"   </p>",
"   <p>",
"    Empiric therapy is often started along with the diagnostic workup if a particular cause is likely based upon history or examination findings. This is especially true in patients with suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    -associated acute liver failure since the treatment, N-acetylcysteine (NAC), significantly improves outcomes if started early and has few side effects. NAC has also been used for patients with non-acetaminophen induced liver failure. Once the cause of the liver failure is confirmed, therapy can be adjusted as needed. (See",
"    <a class=\"local\" href=\"#H55634786\">",
"     'Laboratory findings associated with specific diagnoses'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233807383#H233807383\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Treatment of the underlying cause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63222787\">",
"    <span class=\"h3\">",
"     Timing of the evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient diagnosed with acute liver failure should begin immediately to identify the cause of the acute liver failure. This is crucial because in some cases, early diagnosis and treatment may improve the patient's prognosis. In addition, timely evaluation is required to identify patients who may require urgent liver transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link&amp;anchor=H233807383#H233807383\">",
"     \"Acute liver failure in adults: Management and prognosis\", section on 'Treatment of the underlying cause'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory tests and abdominal imaging should be ordered as soon as acute liver failure is recognized and should not be delayed while the history and physical examination are being performed. Likewise, because patients with grade I or II encephalopathy may progress to higher grade encephalopathy and lose their ability to communicate, a history should be obtained as soon as possible from such patients.",
"   </p>",
"   <p>",
"    The initial evaluation should",
"    <strong>",
"     not",
"    </strong>",
"    be delayed in patients who are being transferred to a liver transplant center. Instead, the diagnostic evaluation should be initiated at the facility where the patient presents, with results communicated to the transplant center as they become available. Conversely, transfer should not be delayed because test results are still pending, because some patients (particularly those with cerebral edema) will quickly become too unstable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607121\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history may identify potential causes for a patient's acute liver failure, but in patients with severe encephalopathy, the history may be limited or unavailable. In some cases, the patient's family may be able to provide useful information, even if the patient is not able to.",
"   </p>",
"   <p>",
"    Patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    their families should be asked about:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Timing of symptom onset (eg, malaise, nausea, vomiting, jaundice, mental status changes).",
"     </li>",
"     <li>",
"      History of alcohol use.",
"     </li>",
"     <li>",
"      History of prior episodes of jaundice.",
"     </li>",
"     <li>",
"      Medication use, including all medications used, the amounts ingested, and the durations of use. Medication use is not limited to prescription medications, but also includes over-the-counter medications, herbal and dietary supplements, and illicit drug use.",
"     </li>",
"     <li>",
"      Risk factors for intentional drug overdose, such as a history of depression or prior suicide attempts.",
"     </li>",
"     <li>",
"      Toxin exposure, including occupational toxin exposures or wild mushroom ingestion.",
"     </li>",
"     <li>",
"      Risk factors for acute viral hepatitis, including travel to areas endemic for hepatitis A or E, intravenous drug use, occupational exposure, sexual exposure, chronic or inactive hepatitis B infection, and immunosuppression.",
"     </li>",
"     <li>",
"      Risk factors for hepatic ischemia, including hypotension, cardiac failure, a hypercoagulable disorder, oral contraceptive use, or malignancy.",
"     </li>",
"     <li>",
"      Family history of liver disease, such as Wilson disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who develop acute liver failure while hospitalized, the patient's records should be reviewed for possible causes including medications the patient has received (including anesthetics and immunosuppressants) and episodes of hypotension or cardiac dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607129\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination findings may help identify a cause of a patient's acute liver failure, but in many cases the findings, such as jaundice or hepatomegaly, are nonspecific. The physical examination may also help identify complications of acute liver failure, such as cerebral edema and infection. (See",
"    <a class=\"local\" href=\"#H165773354\">",
"     'Physical examination findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All patients should have a routine physical examination, including a complete skin examination. In addition, patients suspected of having Wilson disease should undergo an ocular slit-lamp examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234572#H65234572\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'When to consider Wilson disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical examination findings that may point to a specific cause of acute liver failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vesicular skin lesions (herpes simplex virus)",
"     </li>",
"     <li>",
"      Kayser-Fleisher rings (Wilson disease) (",
"      <a class=\"graphic graphic_picture graphicRef65925 \" href=\"UTD.htm?19/26/19887\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Features of preeclampsia, such as hypertension (HELLP syndrome) (",
"      <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60502 \" href=\"UTD.htm?17/15/17659\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607137\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extensive laboratory evaluation is required in patients with acute liver failure to determine the cause, assess the severity, and prepare for possible liver transplantation. Because patients with acute liver failure may decompensate rapidly, testing should not be delayed. (See",
"    <a class=\"local\" href=\"#H63222787\">",
"     'Timing of the evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory tests that should be obtained at presentation include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prothrombin",
"      <span class=\"nowrap\">",
"       time/INR",
"      </span>",
"     </li>",
"     <li>",
"      Serum chemistries (sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, magnesium, phosphate, lactate dehydrogenase)",
"     </li>",
"     <li>",
"      Liver blood tests (AST, ALT, alkaline phosphatase, GGT, total and direct bilirubin, albumin)",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      level",
"     </li>",
"     <li>",
"      Toxicology screen",
"     </li>",
"     <li>",
"      Viral hepatitis serologies (anti-hepatitis A IgM, hepatitis B surface antigen, anti-hepatitis B core IgM, anti-hepatitis C virus antibodies, hepatitis C RNA, anti-herpes simplex virus antibodies, anti-varicella zoster antibodies; anti-hepatitis E IgM in women who are pregnant)",
"     </li>",
"     <li>",
"      Serum pregnancy test in women of child-bearing potential who are not already known to be pregnant",
"     </li>",
"     <li>",
"      Autoimmune markers (antinuclear antibody, antismooth muscle antibody,",
"      <span class=\"nowrap\">",
"       anti-liver/kidney",
"      </span>",
"      microsomal antibody type 1, immunoglobulin levels)",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Arterial lactate",
"     </li>",
"     <li>",
"      Arterial ammonia",
"     </li>",
"     <li>",
"      Blood type and screen",
"     </li>",
"     <li>",
"      Serologic testing for HIV",
"     </li>",
"     <li>",
"      Amylase and lipase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional tests that are indicated in specific circumstances include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ceruloplasmin level in patients suspected of having Wilson disease. However, serum ceruloplasmin may be normal or elevated in the setting of acute liver failure, so if there is significant concern for Wilson disease, a liver biopsy may be required. However, since most patients with acute liver failure due to Wilson disease will need emergent liver transplantation, liver biopsies are usually not necessary if the liver failure is due to Wilson disease, and transplantation should not be delayed in order to obtain biopsies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We obtain testing for Wilson disease in patients with acute liver failure who are under the age of 40 years or who have any of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A Coombs-negative hemolytic anemia",
"     </li>",
"     <li>",
"      Neurologic symptoms prior to the onset of acute liver failure",
"     </li>",
"     <li>",
"      Kayser-Fleisher rings",
"     </li>",
"     <li>",
"      A ratio of AST to ALT of greater than two",
"     </li>",
"     <li>",
"      A normal or subnormal alkaline phosphatase",
"     </li>",
"     <li>",
"      A ratio of alkaline phosphatase (int.",
"      <span class=\"nowrap\">",
"       unit/L)",
"      </span>",
"      to total bilirubin",
"      <span class=\"nowrap\">",
"       (mg/dL)",
"      </span>",
"      of less than four",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-hepatitis D virus antibodies in patients with acute or chronic hepatitis B. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of hepatitis D virus infection\", section on 'Diagnosis of HDV infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-hepatitis E virus antibodies for patients with travel to endemic areas such as Russia, Pakistan, Mexico, or India. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link&amp;anchor=H10#H10\">",
"       \"Hepatitis E virus infection\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinalysis to look for proteinuria in women who are pregnant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H18#H18\">",
"       \"Preeclampsia: Clinical features and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607145\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging with abdominal Doppler ultrasonography should be obtained to look for evidence of Budd-Chiari syndrome, portal hypertension, hepatic steatosis, hepatic congestion, and underlying cirrhosis. Ultrasonography is readily available, inexpensive, and noninvasive. Hepatic imaging may also reveal evidence of malignant infiltration. As noted above, a massively necrotic liver may appear nodular and does not necessarily indicate underlying cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H414607206\">",
"     'Imaging and other studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Alternatives to ultrasound included abdominal computed tomography (CT) scanning, venography, or magnetic resonance imaging and venography",
"    <span class=\"nowrap\">",
"     (MRI/MRV).",
"    </span>",
"    In addition to being able to detect Budd-Chiari syndrome, CT and MRI are more sensitive than ultrasound for diagnosing hepatic malignancies. However, prior to obtaining a CT scan, venogram, or",
"    <span class=\"nowrap\">",
"     MRI/MRV,",
"    </span>",
"    the risk of renal injury associated with the contrast agents (contrast-induced nephropathy with iodinated contrast agents and nephrogenic systemic fibrosis with gadolinium) should be weighed against the need for the examination, especially since patients with acute liver failure may also have renal failure. We reserve the use of these imaging techniques to patients with a negative ultrasound in whom the suspicion for Budd-Chiari syndrome or malignancy remains high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=see_link&amp;anchor=H39#H39\">",
"     \"Principles of magnetic resonance imaging\", section on 'MR contrast agents and renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An echocardiogram to look for cardiac dysfunction should be considered in patients suspected of having acute hepatic ischemia without a known cause (eg, in a patient with markedly elevated transaminases without a cause identified from the patient's history, laboratory examination, or abdominal imaging).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414607153\">",
"    <span class=\"h3\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If laboratory and imaging tests fail to identify an etiology, a liver biopsy may aid with the diagnosis. It is often performed via a transjugular approach in the setting of acute liver failure because of concerns over bleeding. Our practice is to obtain a liver biopsy in patients with acute liver failure of indeterminate etiology. However, if the patient has progressed to the point of requiring liver transplantation, histologic evaluation can instead be performed on the explanted liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=see_link\">",
"     \"Transjugular liver biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver biopsy may help with the diagnosis of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant infiltration.",
"     </li>",
"     <li>",
"      Autoimmune hepatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Histology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wilson disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=see_link&amp;anchor=H59395417#H59395417\">",
"       \"Tests used in the diagnosis of Wilson disease\", section on 'Liver biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis due to herpes simplex virus.",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy. However, because liver biopsy is invasive, it should be approached with caution during pregnancy and reserved for cases in which a diagnosis of acute fatty liver of pregnancy is in doubt and the appropriate treatment (delivery) is being delayed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link&amp;anchor=H7#H7\">",
"       \"Acute fatty liver of pregnancy\", section on 'Liver biopsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64480134\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary entity in the differential diagnosis of acute liver failure is severe acute hepatitis. Patients with severe acute hepatitis have jaundice and coagulopathy but lack signs of hepatic encephalopathy. Distinguishing the two is important because patients with severe acute hepatitis generally have a good prognosis, whereas those who progress to acute liver failure have a high mortality rate and often require liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differentiating severe acute hepatitis from acute liver failure in a patient with Wilson disease may be difficult because neurologic Wilson disease may be confused with hepatic encephalopathy. Features that suggest neurologic Wilson disease rather than hepatic encephalopathy include the presence of dysarthria, dystonia, tremors, or parkinsonism. In addition, neurologic symptoms in a patient with Wilson disease may have been present prior to the onset of the hepatic manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H69501597#H69501597\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Neurologic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe acute alcoholic hepatitis may present with liver failure that appears to have developed over the course of weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/26\">",
"     26",
"    </a>",
"    ]. However, patients with alcoholic hepatitis typically have a history of heavy drinking for many years and are thus thought to have acute-on-chronic liver failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/27\">",
"     27",
"    </a>",
"    ]. Differentiating alcoholic hepatitis from acute liver failure is important because the two entities are managed differently (eg, there is a role for corticosteroids in the treatment of alcoholic hepatitis, but not in acute liver failure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=see_link\">",
"     \"Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alcoholic hepatitis should be considered in patients with a history of heavy alcohol use or who have an aspartate aminotransferase to alanine aminotransferase ratio of approximately 2:1. However, a history of heavy alcohol use does not exclude other causes of acute liver failure (and in the case of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    toxicity may predispose to it), so a patient presenting with acute liver failure in the setting of heavy alcohol use still requires a thorough evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=see_link&amp;anchor=H418822015#H418822015\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute liver failure refers to the development of severe acute liver injury with encephalopathy and impaired synthetic function (international normalized ratio [INR] of &ge;1.5) in a patient without cirrhosis or preexisting liver disease. While the time course that differentiates acute liver failure from chronic liver failure varies between reports, a commonly used cut-off is an illness duration of &lt;26 weeks. (See",
"      <a class=\"local\" href=\"#H73465368\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute liver failure can result from a wide variety of causes, including (",
"      <a class=\"graphic graphic_table graphicRef67925 \" href=\"UTD.htm?24/16/24843\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79913 \" href=\"UTD.htm?43/1/44060\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/17/2330/abstract/2,5\">",
"       2,5",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen (paracetamol)",
"      </a>",
"     </li>",
"     <li>",
"      Idiosyncratic drug reactions",
"     </li>",
"     <li>",
"      Viral hepatitis",
"     </li>",
"     <li>",
"      Autoimmune hepatitis",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Ischemic hepatopathy",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome",
"     </li>",
"     <li>",
"      Veno-occlusive disease",
"     </li>",
"     <li>",
"      Acute fatty liver of",
"      <span class=\"nowrap\">",
"       pregnancy/HELLP",
"      </span>",
"      (hemolysis, elevated liver enzymes, low platelets) syndrome",
"     </li>",
"     <li>",
"      Malignant infiltration",
"     </li>",
"     <li>",
"      Partial hepatectomy",
"     </li>",
"     <li>",
"      Mushroom poisoning",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Heat stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral and drug-induced hepatitis are the most common causes of acute liver failure in adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of acute liver failure in addition to hepatic encephalopathy, abnormal liver blood tests, and an INR &ge;1.5 (all of which are required for the diagnosis), may include jaundice, hepatomegaly, right upper quadrant tenderness, and thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H64480073\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining the etiology of acute liver failure requires a combination of history taking, laboratory tests, and imaging studies. If the initial evaluation fails to identify an etiology, a liver biopsy may be required. (See",
"      <a class=\"local\" href=\"#H64480080\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because patients may decompensate rapidly, the initial evaluation should be broad, even in patients with a presumed cause for their acute liver failure. A broad evaluation is required to identify a cause of the acute liver failure and to prepare for possible liver transplantation.",
"     </li>",
"     <li>",
"      Laboratory tests that should be obtained at presentation include (see",
"      <a class=\"local\" href=\"#H414607137\">",
"       'Laboratory evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prothrombin",
"      <span class=\"nowrap\">",
"       time/INR",
"      </span>",
"     </li>",
"     <li>",
"      Serum chemistries (sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, magnesium, phosphate, lactate dehydrogenase)",
"     </li>",
"     <li>",
"      Liver blood tests (AST, ALT, alkaline phosphatase, GGT, total and direct bilirubin, albumin)",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      level",
"     </li>",
"     <li>",
"      Toxicology screen",
"     </li>",
"     <li>",
"      Viral hepatitis serologies (anti-hepatitis A IgM, hepatitis B surface antigen, anti-hepatitis B core IgM, anti-hepatitis C virus antibodies, hepatitis C RNA, anti-herpes simplex virus antibodies, anti-varicella zoster antibodies)",
"     </li>",
"     <li>",
"      Serum pregnancy test in women of child-bearing potential who are not already known to be pregnant",
"     </li>",
"     <li>",
"      Autoimmune markers (antinuclear antibody, antismooth muscle antibody,",
"      <span class=\"nowrap\">",
"       anti-liver/kidney",
"      </span>",
"      microsomal antibody type 1, immunoglobulin levels)",
"     </li>",
"     <li>",
"      Arterial blood gas",
"     </li>",
"     <li>",
"      Arterial lactate",
"     </li>",
"     <li>",
"      Arterial ammonia",
"     </li>",
"     <li>",
"      Blood type and screen",
"     </li>",
"     <li>",
"      Serologic testing for HIV",
"     </li>",
"     <li>",
"      Amylase and lipase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional laboratory tests that are indicated in specific circumstances include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ceruloplasmin level in patients suspected of having Wilson disease. However, serum ceruloplasmin may be normal or elevated in the setting of acute liver failure, so if there is significant concern for Wilson disease, a liver biopsy may be required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=see_link&amp;anchor=H65234856#H65234856\">",
"       \"Clinical manifestations, diagnosis, and natural history of Wilson disease\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-hepatitis D virus antibodies in patients with acute or chronic hepatitis B. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis of hepatitis D virus infection\", section on 'Diagnosis of HDV infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-hepatitis E virus antibodies for patients with travel to endemic areas such as Russia, Pakistan, Mexico, or India. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link&amp;anchor=H10#H10\">",
"       \"Hepatitis E virus infection\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinalysis to look for proteinuria in women who are pregnant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H18#H18\">",
"       \"Preeclampsia: Clinical features and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging with abdominal Doppler ultrasonography, computed tomography (CT) scanning, venography, or magnetic resonance imaging and venography",
"      <span class=\"nowrap\">",
"       (MRI/MRV)",
"      </span>",
"      should be obtained to look for evidence of Budd-Chiari syndrome. Hepatic imaging may also reveal evidence of malignant infiltration. However, CT scanning, venography, and",
"      <span class=\"nowrap\">",
"       MRI/MRV",
"      </span>",
"      should be used with caution because the contrast agents used are associated with renal injury. We reserve the use of CT, venography, and",
"      <span class=\"nowrap\">",
"       MRI/MRV",
"      </span>",
"      for patients with a negative ultrasound in whom the suspicion for Budd-Chiari syndrome or malignancy remains high. (See",
"      <a class=\"local\" href=\"#H414607145\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/1\">",
"      Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: Summary of a workshop. Hepatology 2008; 47:1401.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/3\">",
"      Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/4\">",
"      Lidofsky SD. Liver transplantation for fulminant hepatic failure. Gastroenterol Clin North Am 1993; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/5\">",
"      Gill RQ, Sterling RK. Acute liver failure. J Clin Gastroenterol 2001; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/6\">",
"      Lee WM. Etiologies of acute liver failure. Semin Liver Dis 2008; 28:142.",
"     </a>",
"    </li>",
"    <li>",
"     O'Grady JG, Portmann B, Williams R. Fulminant hepatic failure. In: Diseases of the Liver, Schiff L, Schiff R (Eds), Lippincott, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/8\">",
"      Oketani M, Ido A, Tsubouchi H. Changing etiologies and outcomes of acute liver failure: A perspective from Japan. J Gastroenterol Hepatol 2011; 26 Suppl 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/9\">",
"      Kemmer NM, Miskovsky EP. Hepatitis A. Infect Dis Clin North Am 2000; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/10\">",
"      Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/11\">",
"      Wright TL, Mamish D, Combs C, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992; 339:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/12\">",
"      Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999; 45:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/13\">",
"      Lee WM. Acute liver failure. N Engl J Med 1993; 329:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/14\">",
"      Mu&ntilde;oz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis 1993; 13:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/15\">",
"      Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 2000; 32:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/16\">",
"      Kaufman B, Gandhi SA, Louie E, et al. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis 1997; 24:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/17\">",
"      Schi&oslash;dt FV, Balko J, Schilsky M, et al. Thrombopoietin in acute liver failure. Hepatology 2003; 37:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/18\">",
"      Stravitz RT, Lisman T, Luketic VA, et al. Minimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastography. J Hepatol 2012; 56:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/19\">",
"      Agarwal B, Wright G, Gatt A, et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/20\">",
"      Caraceni P, Van Thiel DH. Acute liver failure. Lancet 1995; 345:163.",
"     </a>",
"    </li>",
"    <li>",
"     O'Grady JG, Williams R. Acute liver failure. In: Gastrointestinal emergencies, Gilmore IT, Shields R (Eds), WB Saunders, Eastbourne 1992. p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/22\">",
"      Mas A, Rod&eacute;s J. Fulminant hepatic failure. Lancet 1997; 349:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/23\">",
"      Shakil AO, Jones BC, Lee RG, et al. Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure. Dig Dis Sci 2000; 45:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/24\">",
"      Poff JA, Coakley FV, Qayyum A, et al. Frequency and histopathologic basis of hepatic surface nodularity in patients with fulminant hepatic failure. Radiology 2008; 249:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/25\">",
"      Chavarria L, Alonso J, Rovira A, C&oacute;rdoba J. Neuroimaging in acute liver failure. Neurochem Int 2011; 59:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/26\">",
"      Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010; 16:4905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/17/2330/abstract/27\">",
"      Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 2011; 41:805.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3574 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2330=[""].join("\n");
var outline_f2_17_2330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73465368\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acetaminophen and other hepatotoxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64479183\">",
"      Idiosyncratic drug reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64480066\">",
"      Hypoperfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64480073\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76739483\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165773354\">",
"      Physical examination findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73466383\">",
"      - Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73466390\">",
"      - Other physical examination findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414607198\">",
"      Laboratory test abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55634786\">",
"      - Laboratory findings associated with specific diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414607206\">",
"      Imaging and other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64480080\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63223121\">",
"      Diagnosing acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63223030\">",
"      Determining the cause of acute liver failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63222787\">",
"      - Timing of the evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414607121\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414607129\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414607137\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414607145\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414607153\">",
"      - Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64480134\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3574\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3574|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/49/21279\" title=\"figure 1\">",
"      Acetaminophen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12883\" title=\"figure 2\">",
"      Clinical features of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3574|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/26/19887\" title=\"picture 1\">",
"      Kayser Fleischer ring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3574|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/16/24843\" title=\"table 1\">",
"      Causes of FHF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/1/44060\" title=\"table 2\">",
"      Drugs toxins causing ALF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/17/33051\" title=\"table 3\">",
"      Stages hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 4\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/15/17659\" title=\"table 5\">",
"      Findings that increase the certainty of dx of preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10698?source=related_link\">",
"      Amatoxin-containing mushroom poisoning including ingestion of Amanita phalloides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6250?source=related_link\">",
"      Clinical significance and molecular characteristics of common hepatitis B virus variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14230?source=related_link\">",
"      Diagnosis of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/50/29482?source=related_link\">",
"      Hepatorenal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27736?source=related_link\">",
"      Hydrocarbon poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18568?source=related_link\">",
"      Ischemic hepatitis, hepatic infarction, and ischemic cholangiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/11/15543?source=related_link\">",
"      Pathogenesis, epidemiology, natural history, and clinical manifestations of hepatitis D virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22104?source=related_link\">",
"      Prognosis and management of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14088?source=related_link\">",
"      Tests used in the diagnosis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=related_link\">",
"      Transjugular liver biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_17_2331="Public awareness thalassemia";
var content_f2_17_2331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Public awareness of thalassemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        93 percent were aware of thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90 percent were aware of the need for blood transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        89 percent knew that thalassemia is not infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80 percent knew about the hereditary nature of thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69 percent believed that thalassemia is presently incurable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Politis, C. The psychosocial impact of chronic illness. Cooley's anemia, Seventh Symposium. Ann N Y Acad Sci 1998; 850:349. (number interviewed = 3,478).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2331=[""].join("\n");
var outline_f2_17_2331=null;
var title_f2_17_2332="Anticoagulation and surgery";
var content_f2_17_2332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for preoperative and postoperative anticoagulation in patients on oral anticoagulation therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Before surgery",
"       </td>",
"       <td class=\"subtitle1\">",
"        After",
"surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Venous thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Within first month",
"       </td>",
"       <td class=\"indent1\">",
"        IV heparin or SQ LMWH",
"       </td>",
"       <td class=\"indent1\">",
"        IV heparin or SQ LMWH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Second/third month",
"       </td>",
"       <td class=\"indent1\">",
"        No change*",
"       </td>",
"       <td class=\"indent1\">",
"        IV heparin or SQ LMWH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;3",
"months",
"       </td>",
"       <td class=\"indent1\">",
"        No change*",
"       </td>",
"       <td class=\"indent1\">",
"        SQ heparin or LWMH",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Arterial thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recent, within one month",
"       </td>",
"       <td class=\"indent1\">",
"        IV heparin or SQ LMWH",
"       </td>",
"       <td class=\"indent1\">",
"        IV heparin or SQ LMWH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prophylaxis (non valvular AF,",
"mechanical valves)",
"       </td>",
"       <td class=\"indent1\">",
"        No change*",
"       </td>",
"       <td class=\"indent1\">",
"        Resume oral anticoagulation&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Warfarin should be withheld to allow the INR to fall spontaneously to 1.5 to 2 before surgery is performed.",
"    <div class=\"footnotes\">",
"     LMWH: low molecular weight heparin.",
"     <br>",
"      * If the patient is hospitalized, subcutaneous (SQ) heparin or LMWH should be administered, but hospitalization is not recommended solely for this purpose.",
"      <br>",
"       &bull; Can use SQ heparin or SQ LMWH if the surgery carries a high risk of postoperative thromboembolism.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2332=[""].join("\n");
var outline_f2_17_2332=null;
var title_f2_17_2333="Screening tests for occlusive vascular syndromes";
var content_f2_17_2333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening tests for occlusive vascular syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complete blood count with differential, platelet count, and blood smear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia or anemia, granulocytosis, thrombocytosis, poikilocytosis",
"        <br/>",
"        <ul>",
"         <li>",
"          May be sign of myeloproliferative or myelodysplastic diseases",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of red cell fragmentation (schistocytes) and microangiopathy, consider:",
"        <br/>",
"        <ul>",
"         <li>",
"          TTP-hemolytic uremic syndrome",
"         </li>",
"         <li>",
"          Purpura fulminans with DIC, occasionally",
"         </li>",
"         <li>",
"          Antiphospholipid antibody syndrome, occasionally",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia, consider:",
"        <br/>",
"        <ul>",
"         <li>",
"          Heparin necrosis, some patients",
"         </li>",
"         <li>",
"          Purpura fulminans with DIC",
"         </li>",
"         <li>",
"          TTP-hemolytic uremic syndrome",
"         </li>",
"         <li>",
"          Antiphospholipid antibody syndrome, some patients",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe neutropenia",
"        <br/>",
"        <ul>",
"         <li>",
"          Immunocompromised; opportunistic infections very likely",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilia",
"        <br/>",
"        <ul>",
"         <li>",
"          Cholesterol emboli",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Partial thromboplastin time (PTT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimally prolonged in TTP-hemolytic uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged in purpura fulminans and DIC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged if lupus anticoagulant activity present, and assay sensitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cryoglobulins (occasionally cryofibrinogen and cold agglutinins) when location and history suggest cold occlusion syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirms occlusion versus other mechanisms of vessel injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May suggest platelet plugs instead of fibrin thrombi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May suggest cryoglobulin gelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May diagnose calciphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May suggest cholesterol, oxalate or crystal globulin occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Special stains for organisms in immunocompromised hosts, when appropriate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Basic hepatic and renal function screens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatic function can affect vitamin K-dependent factors and warfarin (Coumadin&reg;) metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal disease moves cutaneous calciphylaxis higher in the differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ANCA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To reduce the likelihood of the uncommon non-inflammatory retiform purpura presentation of granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ANCA may be available before permanent histologic sections",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cutaneous manifestations of microvascular occlusion syndromes. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, Spain 2008. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2333=[""].join("\n");
var outline_f2_17_2333=null;
var title_f2_17_2334="Common side effects of AEDs";
var content_f2_17_2334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59755%7ENEURO%2F78896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59755%7ENEURO%2F78896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common side effects of antiepileptic drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systemic side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neurotoxic side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Nausea, vomiting, diarrhea, hyponatremia, rash, pruritus",
"       </td>",
"       <td>",
"        Drowsiness, dizziness, blurred or double vision, lethargy, headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        Nausea, vomiting",
"       </td>",
"       <td>",
"        Sleep disturbance, drowsiness, hyperactivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        Nausea, vomiting, anorexia, weight loss",
"       </td>",
"       <td>",
"        Insomnia, dizziness, headache, ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        Infrequent",
"       </td>",
"       <td>",
"        Somnolence, dizziness, ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacosamide",
"       </td>",
"       <td>",
"        Nausea, vomiting, fatigue",
"       </td>",
"       <td>",
"        Ataxia, dizziness, headache, diplopia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Rash, nausea",
"       </td>",
"       <td>",
"        Dizziness, tremor, diplopia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam",
"       </td>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        Fatigue, somnolence, dizziness, agitation, anxiety, irritability, depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        Nausea, rash, hyponatremia",
"       </td>",
"       <td>",
"        Sedation, headache, dizziness, vertigo, ataxia, diplopia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perampanel",
"       </td>",
"       <td>",
"        Weight gain, fatigue, nausea",
"       </td>",
"       <td>",
"        Dizziness, somnolence, irritability, gait disturbance, falls, aggression, mood alteration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Gingival hypertrophy, rash",
"       </td>",
"       <td>",
"        Confusion, slurred speech, double vision, ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin",
"       </td>",
"       <td>",
"        Weight gain",
"       </td>",
"       <td>",
"        Dizziness, somnolence, ataxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primidone, phenobarbital",
"       </td>",
"       <td>",
"        Nausea, rash",
"       </td>",
"       <td>",
"        Alteration of sleep cycles, sedation, lethargy, behavioral changes, hyperactivity, ataxia, tolerance, dependence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide",
"       </td>",
"       <td>",
"        Nausea, vomiting, fatigue",
"       </td>",
"       <td>",
"        Dizziness, somnolence, headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiagabine",
"       </td>",
"       <td>",
"        Abdominal pain",
"       </td>",
"       <td>",
"        Dizziness, lack of energy, somnolence, nausea, nervousness, tremor, difficulty concentrating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        Weight loss, paresthesias",
"       </td>",
"       <td>",
"        Fatigue, nervousness, difficulty concentrating, confusion, depression, anorexia, language problems, anxiety, mood problems, tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        Weight gain, nausea, vomiting, hair loss, easy bruising",
"       </td>",
"       <td>",
"        Tremor, dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigabatrin",
"       </td>",
"       <td>",
"        Vision loss",
"       </td>",
"       <td>",
"        Drowsiness, fatigue, dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide",
"       </td>",
"       <td>",
"        Nausea, anorexia",
"       </td>",
"       <td>",
"        Somnolence, dizziness, ataxia, confusion, difficulty concentrating, depression",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rare but serious side effects of AEDs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, lupus syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethosuximide",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Felbamate",
"       </td>",
"       <td>",
"        Aplastic anemia, liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabapentin",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lacosamide",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, hypersensitivity, aseptic meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levetiracetam",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, toxic epidermal necrolysis, multiorgan hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, adenopathy, pseudolymphoma, neuropathy, ataxia, lupus-syndrome, hirsuitism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primidone, phenobarbital",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, hepatic failure, dermatitis/rash, serum sickness, connective tissue contractures (eg, Duputrens)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rufinamide",
"       </td>",
"       <td>",
"        Stevens-Johnson syndrome, dermatitis/rash, shortened QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tiagabine",
"       </td>",
"       <td>",
"        Unknown, nonconvulsive status epilepticus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topiramate",
"       </td>",
"       <td>",
"        Acute myopia and glaucoma; kidney stones; oligohydrosis and hyperthermia which primarily occur in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valproate",
"       </td>",
"       <td>",
"        Agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, pancreatitis, polycystic ovary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigabatrin",
"       </td>",
"       <td>",
"        MRI abnormalities, depression, weight gain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zonisamide",
"       </td>",
"       <td>",
"        Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, aplastic anemia, agranulocytosis, nephrolithiasis; in children, fever and hyperhidrosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2334=[""].join("\n");
var outline_f2_17_2334=null;
var title_f2_17_2335="CDC algorithm for GBS prophylaxis in penicillin allergy";
var content_f2_17_2335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    CDC algorithm for GBS prophylaxis in penicillin allergy*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 304px; background-image: url(data:image/gif;base64,R0lGODlhSAIwAcQAAP///wAAAIiIiERERLu7uyIiIpmZmd3d3WZmZhERETMzM+7u7szMzFVVVXd3d6qqqiAgIEBAQKCgoODg4NDQ0BAQEPDw8MDAwLCwsFBQUHBwcICAgGBgYAAAAAAAAAAAACH5BAAAAAAALAAAAABIAjABAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMigGPkJGSk5SVlpeYmZqbnJ2cjaChhwGiRaSlqKl6p6o/rK2wsWyvsjm0tbi5Xre6M7y9wMFQv8ItxMXIyULHyifMzdDRNM9FAwIAAQRnAgMA1r7S4eI2tJAF2iUEp+ot7Cvf2THfKO489SPs3N7X8SUHkAhKUBtHsGA5AwAEJDBxr90zeOh0NCSib54KBgEYkBhYsKO0gwAw/nukYEGBR+dI/x1Q8CiggAInS54MUIAEAkgIIQJoQHKBOnUGBEDq9k3oI40iZtYc8GjAAhIDWAYIuLJlQpgBSrKrGqBBPqL8CKhjmQApgH8HNnpcyxabQIQIaor498AduwZUy748sCCBgYkjECjYh42AgJIAFAhQdw3jg4RgMUbEd+rlggWKoTYImRHvWb0F+Pq9203EV8LZfnoLmNCvwLawCZZDyYAB00d/15GaiVsfgAK5TShEiZrATYDuDMitKED5CXcIWAtgLWJeAOWRgpYGzg44ZcjFobP2/jq2+WggRQgGsOC6uqd3qYP/nfvpCLoAHCwNe9g+AHcYadRAZP2Q8N5VlxVwzf8I3zwQwAGejeAbd6QM+B1zhYmnAkfnddhKev8lQNN1mNG0lVQPTmhAiXJVh9J+he2EUz3HFQBWQpCYxaI3TfnH4yPXcJXidsFx5RUpGKZ2SnRJIVSeh1ACwyEVEeJg0TBRZqnLlFDcpkBaOVz5BJdalmkImcigaeaagKgpjJtsxrmKeXDKaWcddfaS5518vrFnLn/2KWganhRq6KGIJqooJoM26qhbj0YqqRiBTmrppT5UiummnE7T6aegIqFpqKSWCqmpqK5xFAAGjNomLAck8NhOm6X6EUysDrTorrz26uuvwAY7yQmWPZAAmLZCE4BCzakklQMouJqsCL8MENf/NUYVwMACty00LaBBLVvhZgwkMNkI0k77yz/dlKuRA0f6+G0tJM5EX3VOPjkvD8R806o5+QWQwIL7xnJdruNydi61BffQb2NlmSBSw7Ac/Juzj0DrDMU7PCyCUVOpYxXHH5Fsi8lRUpDBBW5dkAEFKL8wAcyQUjBBzOZBEIDOPOPsggUBRCBBABJEEIAFPsM2dCQSJN0CB5Jw4HRbFlQASQVIT60CBZLQrLVHGkCiwdcrGP1IBGSvNQEkN6eNwtJEu+2R0WjLjYLVFdjdEQYBYKD3CRsEsMHfBdVNOAlrt3344h6xzPjjkEcu+eSUV364sJhnrvnmnB/B+eegh85o/6TpPlq6WnKeHo7qg7J+KpuuK5u067EDKmntd9JuJ+7J8J6657vfroVOUZxmh+5Z+AZDgUeIvLArwvMAcq0rTJSkWM8YIJWCKPz7yPPOYA+emDhgmILIBThQGqvedgw8CdOfMA/58hO8Qja+Kf8C8+TTX0NmRvBdMSr1krNwzwbEq96yPra+EjhnBsYLgv++MzFvaMx9ASxBAQ9wQKjYrwUTJFZp9OcC5qEghDIw1/tM14MC7gQBBJhJTqQSkBM9ogHXywdWEDOCKqnAex8cwEyEKLC0KGl82CKJRrKCGxK0Sj0BiYpVuOE9AzggRwY6RWb+YRYdIE9CcsHLca5Txf+i0AYbUjFAFUcAL/gN5joAeUlMfOQ9+aCxidbg1iP8MiMRucYaQuReX2b1MSXWiARKWWIa/6GNA+0vejsoYLkM4BpjeaMb6jgAaSR0oyPupS/5+s010LeCVnVxAN1olTa450kCaQQB3VigC0XwRAAwCZX/GRJhsEHILH5sMCQ8WQbhV5NJBmYw8xOAu/KzGVnCiASWhOVO+DPC0IDyBK3ykTP34chdDox93PoSq2ryQBEEyJaxBF/6sIGtmjCJScuDpA5AhoCRQOIA30BLd/KVQyQRiQRVKmcK+DfKU0DkNNZ4YAxjJNBa3jJIupzHS6biI3e0hwHk4dcKCzlFEdH/ZJcJjURN4uEcMbXnAQNwACWXaJgR/nME2rvnRrRR0mtc8Zv5fBC18LmgvhBAAaFU6Egns4AxBoSkNSHAsXQaT9K1sEUAcA2DIKrJCq2vn/PJKAAcpDFJMq8BCKGkj77hjoP6cx/ntBBSs3iAlUSRqhW5oAikahpWNEABCZCXME2hwRbhRz8WrI4yI4Yumi5FriJogF/K5S38DSaroVyng5DF0GdyBp8a+6ZCuEWww7TPnBnZSTqdGICnKOCohq2OAqj3SKdKD6oxJE5Oq3oWqeCwk+JTkQO3h60G4khgoSRMWcOC0CRmhaXjLAFTEnBawqBFH/8aTlb8Q8qtTgV6/8MEI1RehDADmNEqa/1XKDebGNZko1xT0a2EUMJUaqXWGiK7rniVCtxdsmeBGlRijO6zPdQm17rg25A84aCAAIPii4hQql7n6dsSDthkCD6EAhC7g1j1srUs9FmEzSTAN81uo2vqcDA0FUzBtrDBY4jgFDZsAqaguMQn4CB+ZwoYIbh4DCKWkglMaOJ4AAbGKHRB/lDcAgbQ0B+R+GB8G3wbO24otzeSXpRLgN4Pvm4IzDCWj4bsAvVFS3wuqPELtLxfLC9MzAN9MAt4DD8iB7kFXJ6BFTnTRbSswMLEXACeX6DiH9AvWzsGsXB8G2cW4PDLaPaBb9ishRzracfYI/+LRqwxxifWcT49hIRxFfCuHHHFyWeJ4w6fwpPpjkVgXRzBRUlgT9ZSub070diViBgAIh4rQ2f9LqfvaLG5rFWK16UiTq54lCoHOrtzeZY9nWRPBMhxujKCNi3veRun4Lq2GUuM/RrgAB3OMdozRthU7BmJA2Rricqhzk+uc+7fZqTd2UBArVLqbWiXOtxXbh2kVWOt4uSStAvQ317QGlppBoCQnolVqhn4MWv6pT/a5jeoU4qCcgnAnmA6SRAX1G8GpTIerIQywV8Zy3ay+teYjOiCDm4MEDeAXOYiYf4cHhTEANDElsEMcRNWLgK0sd9l0aFognJr+mVz0dpYZhv/u5KOBSq9AZIxZ8SWjr0DiETooFRIWsTk6C3te0lvjRE7YvoIczcQngmVy0InigCTZEeEDKfPGEMG9hJgBtRTRYFJQsltE+d9uNdmjlAre/L3wjXKbF8wukBMngFoR4MubdLc5fMNeE7n2o03gLFqbknjAQft9iO7Lhkq0jLXddrmKKf3PhoPazighmeVO2u4/uAj2jLsLO8OtCYr8AIkSJmhtdAI/OLDqEvosSqC+OlvbyC6ojMh0Op5CZz9mWtwzzJ7NjHgWzly0RJ+IzmB0XOJgljnH5uvACUX/giNfCIpX7nt/P21X66wqB5LIZvxfFB8bxL7SXb0LLdMhdV0/1JnFsYngO7FPiqkfznXQQzjWjRWd5WHG0jCXmZHAiWSANenRH3RE0JygSSAXs72T/cWHMwXGJEQENIUWwFAYdjBdKLkItflQf8WHrm2acglUL+lAOKnS9HlUTwULSDGFdBCQiKoWyVIgz9ibUdEhInVDe2BEPpXIjRhP9kyesdhbgBhejXobi6RI/S0XzZyeipChQ6Yb4LSdSpQYB7BYmiwd2kAh6iTYTjjhmUwFGiAh/rSKGoYJXboh2rGMX/YEa0SXIsHgW4AYz3gPzyWaFYwiDfQZ1GgiF2oBKhEZH1IL2rAFJCnaJHHiGcWe1wAiWu2MNz3ZkZAiY4YAyVWI/8aESuwuDGIWAbH0YknBn9fxhCZuGaCZg+iOAWqWDv0JwCbcWjn5yixw4IGwEW5FHBndB024mOlRQIOoBi08GyIAY0IQGyh5WvvRUPNZj7JBgnaUGpa4U/M+B7wphxM0UjTiGxY1lcighjm6BNMFDHxUGoLcYr8kEbK1SPrli+XZiAzsRgy5A1Hho16BgnniG0tGBK2xWtS6Ec5wQ0KQhRHFhgBoQCP8QCPtYf6dgSVtBD9hhdPhw218k7ysRe1BEZDh5LUcmGh9l4pB4Li6H2FAXGKgVABYZJT10wpqYJ4BwQR1oACoJOL0XqoNXDuVVzsdBV5pnOM0T3vOFcEM5L/3qB+DPBJdEUXdwFzhvGRT6kQUXUNYhUVaVERNRkSUbEA5TJ8C7eLBnME5PYgSoUWqzdUprFUlMUbj9BmTbJfiXcfv3Z4DHcl5BFvKXgad/kgeblfjUlZRFCUpWEtk6ch8SYf/Ph9UPQxMHQLoocsdhZq5WYdj0cftjEju+EkjgchWYEQ0jiaDyJRN2JnDwQyQHKMfIgE5gcT7UJYCahargZT1/hPJuR8ByNEzpUi7WdftKIw7+d5Y4iAZRYVwxmP8KgPsVJz1FV3+BMaheWUawVGvzcR/0dZ3zRXodQgo/d5gxGFX1l/DRcjgKVZeUWbyymZLTeLQ8CCcqFKHHVd/wXiIODTknHnHfHQgdLGUTyYn0c4ZSERE/momvMBoF5YZgSaBEUJCbVSgpipDd0SeLj1XwwCkLdwhZRFX8vinz8iS0RCXydRJM/ibrCJEo1EkbuEIbYJVfcTiFdAiXYApNiFfpwEB6gYA4wWBHJZMV6QfXzgpPC4DLboBke6PAY2pMj4YVFaJkv6IVpKpLDjow1Dil5kYElaCF2qCmlqBEYVoMf1B2SaGLCGpGZ6pZXIB2uKCnk6BEyRRN0gFEUIg31Apkp1czJwpmdKCHsqCosKBP/QIiehhYFKYXlApvL2QMBGFQxpjyyhLRLJSM2YDfZUElq3nWPnUVZGB416YP9+4CDUwxMPgJvXWakgdhzyMUg+dUm5JJoHpw4C0kwmp5Jl9lcKkBnsQHF4KqZ08KgjEKmAKhRimaxbagKrF3ZokZq44Q4FtFaRWRjYajEF8Fjs8FO1tnCqqqx00Kc48qcPyRRDeTy92GIa8x6ztR7wqUX+hamr5V72ejDqwz334EPwyp960KY4Ai0daIh4AInMmBTcQFUw6h4MaUSpBWBNKSIxahkYERy34am0SrCCGK844IhCOgroOi9xGgOJBqWsCrIUk7KwsaqNILOyIbKA6LJUkEBsAGSpqqE2mwRV6gc0uwiVckUKuwLBhFUtoEcL+g64cXPyNlPhYxe/CJj/9YMl03oCLKGfA2WnSsgIQ+sIPNAXuMQDOssC+CR/LlAUcjFIfFacKMCzWAumKlCoPRsmd4umJ/sClGRnE5UVUvEYmQoeLHiUuFVvQYgChgpuG3dfNPVZuCZphaEUmQQQl0ZC94aDTLsQyoil2MkClyoXg8u4MVJtpNYTpAtvM3EcgzGQdxC2iRAoFMe2bbVA0jQAWqkP6YlEgUdzKnAYGlR0jRtrzolrIIpaVItp0xZwDTRw1nBOsNRNWJkptToyIoCrKoRLmaR1xZFzioGUzjtY7wKsthQaoLq8C7u3LUBuNYF0vIsN2jGavMt994ICgiEvoIeLW8WXAgFmTGJ7/8YTmvoDeoN3UxcnCVx7A6RYrfmZv5npmZNHwKUXD0gXmumLs6z4WIPkvhjCe92wu1iFhA3kVsTCf2doEczVYLb3v9gDH0jyWOfZe7+XVusjEs5nfHs1mSA0r6U1W0aZkyZ8lEFolNRJwaWRDed5wXSIAx0kbxxMFJpGuKgawv+kQsQJMKrGW9tlMUb7dZ2ZDSzCDkdogfqTgRt4XPFVQ0qhvDjAsN0oSrNlhmGxhKeLG2ZsXAKqDUiHokqcpUsQtCyAUjIgh2vAhhhEtzhAyB6GwRKUt6bQFGD7s8sDyb2jvskCs20Bu4igyeghyR3CyWdSQl4rB6tYPm5mZaVcA/+YbAUlOwtiah2jrLiODD8t4WW0BLlBIBSTkcpvS4anrItsfMg6zAIgI07ETGR5Z8rFu8x5+MorF8tNh29I2y5MhaxD8C+7rCkNIbcEKKVZS0wiMGE6AMhwd0KzTCk+WkVMdDCfdhXfpr+0TMlFqm2hVmdHJkiy0rmABBPX4LYjYCwZShmSq43caBag6hwKSblVm7m/pS1fkY6lpc8Wic8yeYiIXMLsAbAHObjMIUSVVkX09UcT3c+yEs+1tg+bq87p1s4FTUm5eQWgrLcpYB0ml3Cg8ZLwDFqPIXMjBEy+ZdNb2b41gZVomVwC9RPnW1fHC5O8ZAIHLdRDl7y9t3X/4stMPPlCUYUQllTUzqGDIKmk02e9F5rV+5uVdFYRxqweyLQg33SW4tTVUBV1zNFN1tGheeEYDEKpVBDTiqoCsJxcfnmaWuV3MLUchFYaFzXYge1TQFWXPHW95gJUNiEJEfGhDUdRhJlaKiLVZzd7zWIOjMmXjj0PjH20D3jRwuFOgzHaK/d4EuVRPQgms9lTkR1Uhk0YBrxL/RDYiUeuA2CuUcDXg3AMyLpWPqReXwtaAnLYPYRX8iKwcZFXZJ3MCYFXKJDUNcjCJYCc4QdZB6JiRAyc0lkazmcRntWj36xd5TXdJubBy/kYgIWs9slZxwe5NGxfIlHc6CCw6tlD/+/qBMItCMcgXmv1gcidS8Qx2TTRvCPjIE72gaG2ICxqEe3Rs9ht2QqauEbRoGXYqSp2x14YwP0w4QRT4eiN2n01Fwoy4VFsPh1LTtmKoxQuzawLFmncXf0gJOg1XR0L3HPrx0/A30SgYH9A5AKW3i9Azu0g3cNtyT7gJQksBOL8B1N+5CguD+c8A1Uu4E6eKqu8FgEeCGG+yFcOJWMOp186zHFy5kKb5p/7u+sz2P2QqDndsqYjOnie53q+OZ6sPHIOzbLA5pYTCtTg57kRX2U3oQJzMTSBbgUAS9Z3RkQ76Jcc1jMYd/Qxlfv1nfq5TjCImHrd15Tu5XC2PvnMCv9zbhzUUVRb2A95ZLBiO+qoQg0Z2iq0FZPuxZTZtN6u3iym9d9iLuuz3mV7JIWskIWtt0dc8ej7ZQ3LDuyvIuylIuhyQO3SbrK/c+2hYu1wwO3a3uTZ/u2d4u1uQO7ijubhfu6Ysufs3u69ou7w7inxPu/BTu/2Pqj3nu9zou/8jif9/u/VDvCPo67YDe5+UI3KLfCtQES1O8ru/vAQjzkm0H+JEeoKzwjWgkqgarpCuO7PkQD6oWdH5tLSfPGDYC2M8Z2XsbgWbSm/cBPleNfWbPKIUJLfY3l4Z+578AvuENi+7eM07wf9NhKGEcQdfyk8fwpCLuRB/wcdB/N0fPT/Lk8Pp/CBPd70uKDz+471HaH1H8v14aAyLEMKLuM1giL2LfMyYB8NPLMzOxMpbd8zaw8NcPMITfModR83c98MVXM1WeMoff8IWLP30BA2jzA2kmL4AYD4hK8Ma/MIivMojx8Akd/4yEA3l4L5lt8MfOM3ltL5mw8NhmMpox/6pn/6qJ/6qr/6rN/6ThPxsM8rMB37tD86ru/1Zc4EuO9Frn/aXveIXtr7u//mKxb8tz9iMG38rT/83lwFzK/AvY+GgZ78ahr9z0+U1J8K1z/tNCBjWT6AalBicqkmSg60VojMTXX8xMKh+mnLdJrKxOaxLHAb2kMwUQv+uCiN5fzV/z8OAoAQBAhwouk5COoZEK4807UqDCcOsOlOEwK217BoPCKTyiWz6XxCo06hy1FgAA6DmKrRUsKSDWyjcewJCqdF4oEM034qqrROR8lrPRe8jszzfOnkAN3RGPolKi4yNjo+QiECtKkQFJAYGJAEHGwqLCBsqg2QDCwAwASJFFx+2jiYpTRsCq60LIQZJMwRBCkEJGCxhGIKaZKYABJBgrnsLJACAxAkABsEAlwGXBFzjmxjoeiSCGieICBAk+xakh/8lvDAI3Qi7wzMi+S0B1yjaI8qdSqFJGYGDyJMqJCZJE4qElx7sGvPiU5ushQwkGbBAgUtUglJc4CNvxnUDv/4SICSoq0TDRxgI9grzAATPcKoEhdggTJUC4cg2hFk4KQWuqDVKgAzDINgAGClGADzhDkA6IaiSCCogYkDwQaYYRCAwY97YcfugAhAYoqcGzvW8vlzLt26du/KfVgyyyYSWlowiNYPQNNr6HSYAKnvREYaBq6oOBwTxR6JnVDKzHn4ZgxVBuB5IzQH7+gbhBwAE3D5xV9QmxLHOEZCDQoCvwYwqHoYtdbVjPsa2NOvbA7hGgfU24R5GhXJAkwQJC19OvXqb2RYiaGF2t4eCBQAwGWgKZe3BT7OXJztWgPRK1zdKMDxvAqKCRS4f5Heqs2PblQptVZoMhRUV1DuieX/VQsCJICUJqcokJgbTYUzA1dBHPAOdIRxohUKXEXVwgPegLdYDyMekNZete20ynxxFWidjDPSqFBB3dDDzygtULNNP4IJEY0pqKT3Q2MJcFFRXw6tAQ99lGFyAmorEqlZf1YVI8JsA/JRnSHfIBAEMtNUoxYL78xmAjEpvhbVbMIAE6GY8fQYgGqgaUELYdUgcI+eQgGUQkfb8CBQaTUimqiijcSo0AP5FbFAY6Q1+lOlNLKE0KWLctqpp11+ikop022aUKnWZXrQqaGy2qqXrr5K3aqw2kGrrbdaNyuujOgKSa+7LvErsMMSy0RBqT7RE7DCMspETkAliWlcNTBb/6y11x4yA7JKEOeEA5BSS06DSlbIa6xKqKIsCn1Aoa4ACiynxLYEYluvvU8cO+0S3RobALjUxqCWCCU6Uu0ivT5rA7uNDDCALuUiMS+o91JcMVBd/EmCAligRgID/FDJlz2sBODKLCUv4AswEKuXApokREvkU4Q8+aHGoMQi1cvJsOAvIVJFJ+sRLzeQbnH5vAxDcp8EcUkCJ8NEHxsP8CPAPfkgQNsIRHVzTRqtnHKynUcYbLHZsN4hUiBiYYFADgFcNElEu8hQVgEjQfQuhAIEEUNNzkDaQIkLM7UTNUQNvDeGCYLoFVkFaMeJb8uQekR7LJq4DyeXy6wk1WEUkP+DOY8BQLqHg/Cg+UoOO+XCd6vgrdHdk118tu1n3yEZC6RPo0YaJYjVV7x4EGKkAd2UYCXgLkxKOBceSYYC8v05YII2mMjBQvWHSlfqpMyZ2MJlzRMQ2CYG5NSDKmzYZsDk94jP5LvDMzibehnpru8MZd/e/6Jpy0dSAmAbADh3AogI7ARiida7ULcevWGOP8vrwlliBoc0IOkG8KFKAjIIIuLVpgCtW9e5hmBAo2HjMmXgEAFeJ5708YgK76Lb6cLHl+G5DG5P8R3NZPcisvkviPW6w6ASQJ9vbIwNN9NRyxTIJ+MV8HzKI4hyUsCAS1wiWlXEBW0wFqVsECJpKXL/D34m1r2hwaNoISlO/A5wxZKlohqXQB8V1EcFXHyhTlZj4w31MBseMsYARaxZ7YRoyGHxDwAKiNlBEpQQ9pmRUtU5HI0SechL4sWSCpmT/hzhAIIFrXLUUcBUZqRJTKLSUqmcQglXSS9XwpJTp+zfLPFlrzlJoZax3GUi+LewRSgLWb98hC6bUEzTzEUBITMmL5tpyiR8I4H6UQRO1qgtfSnGIMcMFiT41YiE+YCU53iTsZxpTqEdARdusAIvqMnAfwmTkcRsJTCL9y9mKBMB43JJLJpxzn/eZVUFaABP+vkCeFyDBQPISDXG9o82fg1lXbOmLDIGjioJQWptAFkg/xaq0bgVYZv+VMLO9DGChq1AbH0iGdNgMByNCUMbCwXGAdy2ApicDEkhYWnYFCARrm0oCSIFKFH3B038QG4OCxoFvHhQyhTQ5zIiIYnMUIiH2bGAQk8xg2LSsAq5rWUiTSUd74CITiU0LhhpiFyGuDRViAQBMGOxSnFEBzrVSM4bswPfW/1hAM4FZoNCLSphbYQEsZwCK+uKzY5OYBt/lSuqXGpMNZuYP9kQSjHsU2Zy/LKHzS4zW2dNwvWGIxrt8cyBGckJ7yyBDRgGYnvRs+r3IFlWbhY2tww5rA4fJJPSNVYWQf3bCMYYSFT8h6I6COB5tLpYzYjwFNKkyAxHev/GJXzQgb1zSgPvR0cFzvVydmyJJbi7V9peYxP3HKxu29usP6xjRbkIbjQgwyI4Gnc9WOqHcsPzCyMuqE3Z7EQeA0URPFpXkksQYx7KuKcSGO9ZSBRGDFuiyNOuA70yuG2C3evhKAzVU5RkrygTAUlGnHguIf6wOVfMKXF2OKCL+KQnQalKFuPYlh52cUgByuMcw/LH1hIytXwM5CPHmLBEFu05l4zkQzp5WfTkZZSfHMQq4wrLoWyxlbtc5B1PeZda9rLZlmTmM6M5zWpeM5vb7OY3w3kTXooznets5zvjecxk3jOfR9vnPwM60EwWNKEL/Wc9GzrRii4Wohft6Ef/u6rRkJ60bj1WOkmbi1iWCQ8hKe1pRrPi0hTDdBRWSONPo5rRDCqHEF72VCrmOdaynjWtZS0DNqCGDDdjQBpT7etPvXQEBQxLBiMp6IJoYkGu8Eh3f+1sWQpSG/rlQchIbbEChWF6B5iFMp/t7RoN5hjDZuErDY3tGEAwPt9ed678cYkswOPVJEz0uV1yvm8Mht36bpW1K9bvfQOcmor+d8AL3gQKZOACPrlABijwZ4QrXAgMd7jBK24rCAQA4xoPtMYznnGLgxxWEliSBAI98r6UPOQq/5QFKrCJClgg0C1/ecxXbnNOaWATGiB0zkmw85sDPVET2MQECD10EhQ9/+hKp1EEAhABQzf96UufunUwEAAMGNrqWKc616cjdah3PexiHzvZy272s6M97WpfO9vpXeu3wz3usVaY3Otu97uToO3+7nOjCB5pvY+a7wqzst8BHwnBfxnJhTc8K/ncd8IzfoiIHzSQFx953O758U+2/OVJTGbNK77zQ568UYsAzkPIk5aiZ3QTcJGkTqsq9TPwyBHEVICfkouZiVcBr2fDt/4SSPbcWq8Xh9Qj+0YjqEwA07fEQTfurT7LTvigYmckpk7KICcCazbmS68Cr0BHAGo0wjC7KR+nFuUp4NmIV0C6/Bw4Ev3Gjj6thIV7BDRgaSmDo1Oq5upVaAw8PP/AUQyMlngMSPwXy4SIC/CDIeRE82UD9hWS94VTJVgTPoxJ0hCA/jUNMEBNBIbHRmnDHsnDmGDH+b0LYoHPS1jYCsiU06AEvuXHD9BeJygg59Hf4DlBG6SYRfQND5hADa0QeYgEgdGVfmXEAj0XTShffUxLAsAEOOUEYo1YOe0eHigfCqEUhnBOH/gg6NgVcIlhDd2D6sjAy9xHTmDIHvwNZdhVDDSXDgFCWazfv+BgDlKeEsAC6ZgPJljJ5EyKw/xAGOwADjyAGtxWNkWPDGTKakghHUBPE3peuflAFznWBbYR+fRhP8DW+iAJZzGJDU2OhYxBi6gCC9LOeAUC78z/ISHgwhUt0x3iISUugVjQngtxYnME4VZU0CCiWw6wAe0poX4ozzAu4EMEmAVeVbHpXh5mwdPowPjBzw0NIQzg4ne9lgwpAA0JwjSuRg35QBh4CI2xHyVQRoWtTXjNoGgIzj7N3yyGSrX8AkocXy6egwno0f/5ono4wD7h2wIpDyDMiSVemo+0hf2EB6HomDNOAzx4hBa20Rv9Qi/IkT1m4xo4lB55Iyc0BeJkwzb4w/GFQ/I5IfhgAzGETjjGg4BIIuXA498lisTIwCJxC0FmGkMmRBUWgQNIoCJkV/e9JKv824h4ZCJEk/DVyhX+BIxVRzQ0VTMGpVCSHi3mmCxG/2VefJ4Oht5VSiVpnF49XVPw9ZJWLoS6+MG2/NJXLiRXeopIQeBTkFME+YEaAt85Bp9aAuU7JsLJbIwPEN++2BPt/JYymuUksuX/MIS/fAgZGBReNgE4BRM2IWWSzZsjbFqE+KUiAAJaMpJjWuFhdooDakMm0E0DfcMV9A1/dUaLZKYKQAWLJGBHMRQ5oEAnMNYqgA1AWJXN0OZpYoFifBRHKRQr3II5uiQtgowNMgdPkFM/hE41EYURskREuYJzIkDHzJWS3CYGlkBy9Akf1SZoxABf7p8+KOdQ+CYqPAYprCbiWGVUGoJa/JRaQIRWwUJc3aMEIVNbqMRB+o1NNP8V0HzffMEOSdBlE6lNVjkFVHSV76iBfIoVSpAVQYLeAc0NEBYQAtgnV8XCYSzisCnAUy5X7KBCLOjQgG6n6nQLS3QhAUDQQ16gCXDFhpZofn7oewblHXRWaBxiQc7Gs5xEKIKQONhXBG1GHt1GhdimGEYYFeymfu5OX6iBZn2i+yzJX6xBlUKfGe3oAQTpAWDWlHLBl1ZgAQ4pZZXHJaRDbRJoD0hVYLIE+UwPCn1pmHYOmW4ZaCpKfO5FJ9CHc5nkexjUkMpDUSpPpvzkYCyUd2HFk5rHAI0QRp1DdIGVXerANurlcUpTNqQkoHaOPAwqg6DE65xpesWMNClqY0n/VYlM44f04gbRVqdGah/gw6BipZ4mimgipD4NBL6FyR2MCCMJT5ca6ZUUykXhgcYA0noMCuT01yAF2JgMWEYamCAg2JZCHxNdWnkIWJIEqws4ZblAURgoEcqopAKoKkc+EXgqUCuEgdh81w9oArdKq7f+Eo6+ZCIVpsXo5HFm6vD1T0/gKzzyT/tdElPm6b8igcHaDsNiK64+k+ORZeVBLGJKrFLi2MDOosZaLE6CWcXm6lQqbKWBbMherMe6F8fmoMqaLMq2F8tGH97J7MzKHd3R7M3i7JuV7M7ybM/67M8CbdAK7dASbdEa7dEibdIq7dIybdM67dNCbdS6QAgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenously.",
"     <br>",
"      * Broader spectrum agents, including an agent active against GBS, might be necessary for treatment of chorioamnionitis.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Doses ranging from 2.5 to 3.0 million units are acceptable for the doses administered every 4 hours following the initial dose. The choice of dose within that range should be guided by which formulations of penicillin G are readily available to reduce the need for pharmacies to specially prepare doses.",
"       <br>",
"        &Delta; Penicillin-allergic patients with a history of anaphylaxis, angioedema, respiratory distress, or urticaria following administration of penicillin or a cephalosporin are considered to be at high risk for anaphylaxis and should not receive penicillin, ampicillin, or cefazolin for GBS intrapartum prophylaxis. For penicillin-allergic patients who do not have a history of those reactions, cefazolin is the preferred agent because pharmacologic data suggest it achieves effective intraamniotic concentrations. Vancomycin and clindamycin should be reserved for penicillin-allergic women at high risk for anaphylaxis.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         If laboratory facilities are adequate, clindamycin and erythromycin susceptibility testing should be performed on prenatal GBS isolates from penicillin-allergic women at high risk for anaphylaxis. If no susceptibility testing is performed, or the results are not available at the time of labor, vancomycin is the preferred agent for GBS intrapartum prophylaxis for penicillin-allergic women at high risk for anaphylaxis.",
"         <br>",
"          &sect; Resistance to erythromycin is often but not always associated with clindamycin resistance. If an isolate is resistant to erythromycin, it might have inducible resistance to clindamycin, even if it appears susceptible to clindamycin. If a GBS isolate is susceptible to clindamycin, resistant to erythromycin, and testing for inducible clindamycin resistance has been performed and is negative (no inducible resistance), then clindamycin can be used for GBS intrapartum prophylaxis instead of vancomycin.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Verani JR, McGee L, Schrag SJ. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_17_2335=[""].join("\n");
var outline_f2_17_2335=null;
          